US20070269815A1 - Multitargeting interfering RNAs having two active strands and methods for their design and use - Google Patents

Multitargeting interfering RNAs having two active strands and methods for their design and use Download PDF

Info

Publication number
US20070269815A1
US20070269815A1 US11/602,804 US60280406A US2007269815A1 US 20070269815 A1 US20070269815 A1 US 20070269815A1 US 60280406 A US60280406 A US 60280406A US 2007269815 A1 US2007269815 A1 US 2007269815A1
Authority
US
United States
Prior art keywords
sequence
rna molecule
interfering rna
multitargeting interfering
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/602,804
Other languages
English (en)
Inventor
Laurent Rivory
Michael Poidinger
Donald Birkett
Gregory Arndt
Toby Passioura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Research Pty Ltd
Original Assignee
Johnson and Johnson Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Research Pty Ltd filed Critical Johnson and Johnson Research Pty Ltd
Priority to US11/602,804 priority Critical patent/US20070269815A1/en
Assigned to JOHNSON & JOHNSON RESEARCH PTY LIMITED reassignment JOHNSON & JOHNSON RESEARCH PTY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARNDT, GREGORY, BIRKETT, DONALD, PASSIOURA, TOBY, POIDINGER, MICHAEL, RIVORY, LAURENT
Publication of US20070269815A1 publication Critical patent/US20070269815A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Definitions

  • the present invention concerns methods and reagents useful in modulating gene expression.
  • the invention relates to modulating gene expression using one multitargeting interfering RNA molecule having two strands each of which targets one or more sites on one or more pre-selected RNA molecules.
  • RNA interference agents for example, using double-stranded RNA to repress expression of disease-related genes is currently an area of intense research activity.
  • Double-stranded RNA of 19-23 bases in length is recognized by an RNA interference silencing complex (RISC) into which an effector strand (or “guide strand”) of the RNA is loaded.
  • RISC RNA interference silencing complex
  • This guide strand acts as a template for the recognition and destruction of highly complementary sequences present in the transcriptome.
  • interfering RNAs may induce translational repression without mRNA degradation. Such translational repression appears to be a mechanism of action of endogenous microRNAs, a group of short non-coding RNAs involved in differentiation and development.
  • dsRNAs double-stranded RNAs
  • dsRNAs double-stranded RNAs
  • dsRNAs particularly those designed against one target, may have at least two categories of off-target side effects that need to be avoided or minimized.
  • Undesirable side effects can arise through the triggering of innate immune response pathways (e.g. Toll-like Receptors 3, 7, and 8, and the so-called interferon response) and through inadvertent inhibition of protein expression from related or unrelated transcripts (either by RNA degradation, translational repression or other mechanisms).
  • Inadvertent side-effects can be obtained when the passenger strand of a duplex is loaded and generates suppression of RNA species distinct from those targeted by the putative guide strand.
  • Loading bias is well understood and most design processes only select sequences for a RNAi duplex from which only the intended guide strand will be loaded.
  • Algorithms for in silico hybridization are known, and others have been developed for predicting target accessibility and loading bias in an effort to eliminate or minimize side-effects while maintaining effectiveness.
  • RNA molecules for potentially treating human diseases of viral and non-viral origin are in various stages of development.
  • the diseases include Age-related Macular Degeneration, Amyotrophic Lateral Sclerosis (ALS), and Respiratory Syncytial Virus (RSV) infection.
  • ALS Amyotrophic Lateral Sclerosis
  • RSV Respiratory Syncytial Virus
  • RNA interference may be useful and potent in obtaining knock-down of specific gene products, many diseases involve complex interactions between ontologically-unrelated gene products. Thus, the use of single-gene targeting approaches may not succeed except where a single or dominant pathophysiologic pathway can be identified and interrupted.
  • putative targets can be identified for most diseases. Attempts to confirm that inhibiting single targets in isolation is therapeutically valuable have been disappointing. Indeed, obtaining therapeutic effectiveness is proving to be extremely challenging, probably because of multiple levels of redundancy in most signaling pathways. For example, many disorders, such as cancer, type 2 diabetes, and atherosclerosis, feature multiple biochemical abnormalities. In addition, some putative targets may be subject to enhanced mutation rates, thereby negating the effects of interfering RNAs on any such target.
  • viruses such as Severe Acute Respiratory Syndrome (“SARS”) and Avian Influenza Virus (“bird flu”) exemplify these challenges.
  • SARS Severe Acute Respiratory Syndrome
  • Avian Influenza Virus bird flu
  • viruses such as those involved in Acquired Immunodeficiency Syndrome or AIDS (e.g. Human Immunodeficiency Viruses, HIV-1 and HIV-2), continue to defy efforts at treatment and vaccination because of on-going viral mutation and evolution.
  • nucleic acid therapeutics such as interfering RNAs are candidates for viral therapy, in part because modern rapid gene sequencing techniques allow viral genome sequences to be determined even before any encoded functions can be assessed, the error-prone replication of viruses, particularly RNA viruses, means that substantial genomic diversity can arise rapidly in an infected population.
  • strategies for the development of nucleic acid therapeutics have largely centered on the targeting of highly-conserved regions of the viral genome. It is unclear whether these constructs are efficient at treating viral infection or preventing emergence of resistant viral clones.
  • interfering RNAs which can modulate multiple RNAs or target multiple sites within an RNA.
  • Methods for the design and for making such therapeutic multi-targeting interfering RNAs are also needed.
  • Antiviral interfering RNAs that can be developed rapidly upon the isolation and identification of new viral pathogens and that can be used to help slow, or even prevent, the emergence of new, resistant isotypes are also needed. Finally, it would be useful to have such RNAs wherein each of the two strands of a synthetic duplex independently targets at least one of the multiple target RNAs.
  • Interfering RNA molecules are now designed and produced with specificity for multiple binding sequences present in distinct genetic contexts in one or more pre-selected target RNA molecules and are used to modulate expression of the target sequences.
  • the present invention relates to a multitargeting interfering RNA molecule comprising Formula (I): 5′-p-XSY-3′ 3′-X′S′Y′-p-5′ wherein p consists of a terminal phosphate group that is independently present or absent; wherein S consists of a first nucleotide sequence of a length of about 5 to about 20 nucleotides that is completely complementary to a first portion of a first binding sequence, and S′ consists of a second nucleotide sequence of a length of about 5 to about 20 nucleotides that is completely complementary to a first portion of a second binding sequence, wherein said first and second binding sequences are present in distinct genetic contexts in at least one pre-selected target RNA molecule, and wherein S and S′ are at least substantially complementary to each other but are not palindromic; and further wherein X, X′, Y, or Y′, is independently absent or consists of a nucleotide sequence;
  • X, X′, Y, or Y′ independently consists of one or more nucleotides and in another aspect of this embodiment X consists of a third nucleotide sequence that is at least partially complementary to a second portion of the first binding sequence, where the second portion is adjacent to and connected with the 3′-end of said first portion of the first binding sequence, and where X′ consists of a fourth nucleotide sequence that is substantially complementary to the third nucleotide sequence.
  • X and X′ are completely complementary to each other. More preferably, X is completely complementary to the second portion of the first binding sequence.
  • Y′ is designed to consist of a fifth nucleotide sequence that is at least partially complementary to a second portion of the second binding sequence and the second portion is adjacent to and connected with the 3′-end of said first portion of the second binding sequence.
  • Y consists of a sixth nucleotide sequence that is substantially complementary to the fifth nucleotide sequence.
  • Y and Y′ are completely complementary to each other or alternatively Y′ is completely complementary to the second portion of the second binding sequence.
  • S and S′ are completely complementary to each other.
  • XS is completely complementary to the first portion and the second portion of the first binding sequence.
  • Y′S′ is completely complementary to the first portion and the second portion of the second binding sequence.
  • XSY and Y′S′X′ can be completely complementary to each other.
  • S consists of a first nucleotide sequence of a length of about 8 to about 15 nucleotides and XSY and Y′S′X′ preferably include lengths of about 15 to about 29 nucleotides.
  • each of XSY and Y′S′X′ are of a length of about 19 to about 23 nucleotides.
  • the multitargeting interfering RNA molecule comprises one or more terminal overhangs and preferably these overhangs consists of 1 to 5 nucleotides.
  • the multitargeting interfering RNA molecule comprises at least one modified ribonucleotide, universal base, acyclic nucleotide, abasic nucleotide or non-ribonucleotide and more preferably, the multitargeting interfering RNA molecule comprises at least one 2′-O-methyl ribosyl substitution or a locked nucleic acid ribonucleotide.
  • the first and the second binding sequences of the multitargeting interfering RNA molecule are present in distinct genetic contexts in one pre-selected target RNA molecule or alternatively, the first and the second binding sequences are present in distinct genetic contexts in at least two pre-selected target RNA molecules.
  • at least one of the pre-selected target RNA molecules is a non-coding RNA molecule.
  • at least one of the pre-selected target RNA molecules is a messenger RNA (mRNA).
  • mRNA messenger RNA
  • at least one of the binding sequences is present in the 3′-untranslated region (3′UTR) of a mRNA molecule.
  • the pre-selected target RNA molecules are involved in a disease or disorder of a biological system and the disease or disorder preferably that of an animal or a plant.
  • Preferred animals include, but are not limited to rat, a mouse, a dog, a cat, a pig, a monkey, and a human.
  • the pre-selected target RNA molecules encode a protein of a class selected from the group consisting of receptors, cytokines, transcription factors, regulatory proteins, signaling proteins, cytoskeletal proteins, transporters, enzymes, hormones, and antigens.
  • Preferred proteins include those selected from the group consisting of ICAM-1, VEGF-A, MCP-1, IL-8, VEGF-B, IGF-1, Gluc6p, Inppl1, bFGF, PlGF, VEGF-C, VEGF-D, ⁇ -catenin, ⁇ -ras-B, ⁇ -ras-A, EGFR, and TNF alpha and preferably the multitargeting interfering RNA molecule decreases expression of any combination of ICAM-1, VEGF-B, VEGF-C, VEGF-D, IL-8, bFGF, PlGF, MCP-1 and IGF-1 in an expression system.
  • one or more of the pre-selected target RNA molecules preferably comprises one or more RNA molecules selected from a first biological system.
  • one or more of the pre-selected target RNA molecules comprises one or more RNA molecules selected from a second biological system that is infectious to a first biological system.
  • the pre-selected target RNA molecules comprise one or more RNA molecules selected from a first biological system and one or more pre-selected target RNA molecules selected from a second biological system that is infectious to the first biological system.
  • the pre-selected target RNA molecules comprise one or more RNA molecules selected from an animal or a plant and one or more RNA molecules selected from a microbe or a virus that is infectious to the animal or the plant.
  • the pre-selected target RNA molecules preferably comprises an RNA molecule encoding a human protein TNFalpha, LEDGF(p75), BAF, CCR5, CXCR4, furin, NFkB, STAT1.
  • S preferably consists essentially of a nucleotide sequence selected from the group consisting of: GUGACAGUCACU (SEQ ID NO: 2), CUGGGCGAGGCAG (SEQ ID NO: 21), GUGGAUGUGGAG (SEQ ID NO: 22), AGAATCGCAAAACCAGC (SEQ ID NO: 34), AGAATCGCAAAACCA (SEQ ID NO: 36), CAGGGGAGU (SEQ ID NO: 46), AGGGCUCCAGGCG (SEQ ID NO: 63) and GCUGGCCGAGGAG. (SEQ ID NO: 64).
  • S′ consists essentially of a nucleotide sequence selected from the group consisting of: AGTGACTGTCAC (SEQ ID NO: 1), CUGCCUCGCCCAG (SEQ ID NO: 19), CUCCACAUCCAC (SEQ ID NO: 20), GCTGGTTTTGCGATTCT (SEQ ID NO: 33), TGGTTTTGCGATTCT (SEQ ID NO: 35), ACTCCCCTG (SEQ ID NO: 41), CGCCTGGAGCCCT (SEQ ID NO: 61) and CTCCTCGGCCAGC. (SEQ ID NO: 62).
  • the invention in another embodiment, relates to a biological system comprising a multitargeting interfering RNA molecule comprising Formula (I): 5′-p-XSY-3′ 3′-X′S′Y′-p-5′ wherein p consists of a terminal phosphate group that is independently present or absent; wherein S consists of a first nucleotide sequence of a length of about 5 to about 20 nucleotides that is completely complementary to a first portion of a first binding sequence, and S′ consists of a second nucleotide sequence of a length of about 5 to about 20 nucleotides that is completely complementary to a first portion of a second binding sequence, wherein said first and second binding sequences are present in distinct genetic contexts in at least one pre-selected target RNA molecule, and wherein S and S′ are at least substantially complementary to each other but are not palindromic; and further wherein X, X′, Y, or Y′, is independently absent or consists of a nucleo
  • the invention further relates to vectors comprising nucleotide sequences encoding the multitargeting interfering RNA molecules of this invention.
  • Preferred vectors include viral vectors and preferred vectors are those selected from the group consisting of an adeno-associated virus, a retrovirus, an adenovirus, a lentivirus, and an alphavirus. Cells comprising these vectors are also contemplated in this invention.
  • the multitargeting interfering RNA molecule is a short hairpin RNA molecule
  • vectors capable of encoding these short hairpin RNA molecule and those cells containing those vectors or the short hairpin RNA molecules of this invention are also contemplated.
  • the invention further relates to pharmaceutical compositions comprising the multitargeting interfering RNA molecules of this invention together with an acceptable carrier.
  • Other pharmaceutical compositions include the vectors of this invention together with acceptable carriers.
  • the invention in yet another embodiment, relates to a method of inducing RNA interference in a biological system, such as virus, microbes, cells, plants, or animals. These methods include the steps of introducing the multitargeting interfering RNA molecules of the present invention into those biological systems.
  • the invention further comprises the step of obtaining a collection of candidate seeds of the length n, the steps of: i) generating a first collection of sequences of the length n from each of the nucleotide sequences obtained in step b) above using a method comprising the steps of: 1) beginning at a terminus of each of the nucleotide sequence; 2) sequentially observing the nucleotide sequence using a window size of n; and 3) stepping along the nucleotide sequence with a step size of 1; ii) generating a second collection of sequences each of which is completely complementary to a sequence in the first collection; and iii) obtaining the collection of candidate seeds of the length n from the inspection of the first and the second collections of sequences, wherein a candidate seed and its complete complement are not palindromic, and each candidate seed and its complete complement occurs at least once in the nucleotide sequences obtained in step b) of the method provided above.
  • the step of obtaining a collection of candidate seeds of the length n comprises the steps of: i) obtaining the completely complementary sequence for each nucleotide sequence obtained in step (b) of this designing method; ii) generating a first collection of sequences of the length n from each of the nucleotide sequences obtained in step b) and a second collection of sequences of the length n from each of the completely complementary sequences obtained in the present method, wherein the generating step comprises: 1) beginning at a terminus of the nucleotide sequence of each of the nucleotide sequences obtained in step b) above or each of the completely complementary sequences obtained in this aspect of the invention; 2) sequentially observing the nucleotide sequence using a window size of n; and 3) stepping along the nucleotide sequence with a step size of 1; and wherein following the generating step of this aspect the method further comprises iii) obtaining the collection of candidate seeds of the length n from the inspection
  • the step of selecting a group of candidate seeds comprises the step of discarding any sequence of the length n that: i) is composed of a consecutive string of 5 or more identical single nucleotides; ii) is composed of only adenosine and uracil; iii) is predicted to occur with unacceptable high frequency in the non-target transcriptome of interest; iv) is predicted to have a propensity to undesirably modulate the expression or activity of one or more cellular component; v) is any combination of i) to iv); or vi) is palindromic.
  • each of the steps of selecting a first and a second consensus target sequence comprises the step of discarding any sequence that; i) is composed of only a single base; ii) is composed of only adenosine and uracil; iii) has a consecutive string of five or more bases which are cytosine; iv) is predicted to occur with unacceptable high frequency in the non-target transcriptome of interest; v) is predicted to have a propensity to undesirably modulate the expression or activity of one or more cellular component; or vi) is any combination of i) to v).
  • the designing methods of this invention may further comprise the step of modifying the multitargeting interfering RNA molecule, i) to improve the incorporation of the first and the second strands of the multitargeting interfering RNA molecule into the RNA induced silencing complex (RISC); ii) to increase or decrease the modulation of the expression of at least one target RNA molecule; iii) to decrease stress or inflammatory response when the multitargeting interfering RNA molecule is administered into a subject; iv) to alter half life in an expression system; or v) any combination of i) to iv).
  • RISC RNA induced silencing complex
  • the designing methods of this invention preferably further comprise the steps of making the designed multitargeting interfering RNA molecule and testing it in a suitable expression system.
  • the step of selecting a first consensus target sequence can further comprises designing the consensus target sequence where the consensus 3′ flanking sequence to the seed comprises a sequence that is at least partially identical to the 3′ flanking sequence to the seed in at least one sequence obtained in step b) of the designing steps of this invention.
  • the consensus 3′-flanking sequence to the seed can comprise a sequence that is identical to the 3′ flanking sequence to the seed in at least one sequence obtained in step b) of the designing methods of this invention.
  • the complement of the consensus 3′ flanking sequence is a complete complement of the consensus 3′ flanking sequence of step g).
  • the first strand and the second strand are completely complementary to each other, excepting the overhangs if present or in another aspect in the step of designing a multitargeting interfering RNA molecule, the first strand and the second strand are incompletely complementary to each other.
  • the invention in another embodiment, relates to a method of treating a subject, comprising the step of administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a multitargeting interfering RNA molecule of this invention.
  • the method further comprises administering to said subject a therapeutically effective amount of one or more additional therapeutic agents.
  • the invention in yet another embodiment, relates to a method of inhibiting the onset of a disease or condition in a subject, comprising administering to said subject a prophylactically effective amount of a pharmaceutical composition comprising at least one multitargeting interfering RNA molecules of this invention.
  • Other embodiments include processes for making a pharmaceutical composition comprising mixing a multitargeting interfering RNA molecules of this invention and a pharmaceutically acceptable carrier.
  • aspects of the invention include methods of treating and methods of inhibiting the onset of a disease or disorder using a multitargeting interfering RNA of the invention, and methods of making a pharmaceutical composition comprising a multitargeting interfering RNA of the invention.
  • FIG. 1 Multitargeting of VEGF-A and ICAM-1 using both strands of a CODEMIR duplex.
  • a 12 nt seed region was identified by analyzing the two target transcripts.
  • Various permutations of positioning the CODEMIR around the seed were investigated and the resulting sequences are listed in Table 1-1.
  • CODEMIR-27 and -28 correspond to the duplexes of CODEMIR-16 and -17, respectively, excepting the introduction of wobble base-pairs into the extremities of the duplexes to adjust the loading bias.
  • CODEMIR-36 is an example of an incompletely complementary duplex formed with guide strands that are fully complementary to the regions of VEGF-A and ICAM-1 mRNA targeted by CODEMIR16 and CODEMIR17.
  • FIG. 2 Panel A: Further exemplification of multitargeting using both strands of a CODEMIR duplex in which the CODEMIR duplex strands may be completely complementary to each other. Any overhangs present will be without complementary base pairing.
  • Panel B An example of a CODEMIR showing incomplete complementarity between the two active strands of the CODEMIR. Such incomplete complementarity, can derive, for example, by virtue of each strand being completely complementary or almost completely complementary to its respective target.
  • FIG. 3 Effect of a single blunt-end on VEGF and ICAM suppressive activity of CODEMIR targeting these two proteins.
  • ARPE-19 cells were transfected with 40 nM duplex RNA and VEGF (closed bars) or ICAM (open bars) expression was assayed 48 hours post-transfection. Each bar represents the mean of triplicate samples. Error bars indicate standard deviation of the mean.
  • CODEMIR COmputationally-DEsigned, Multi-targeting Interfering RNAs
  • kb kilobase
  • miRNA microRNA
  • ncRNA non-coding RNA
  • nt nucleotide
  • PAGE polyacrylamide gel electrophoresis.
  • RNAi RNA interference
  • siRNA short interfering RNA
  • shRNA short hairpin RNA
  • SNPs single nucleotide polymorphisms
  • VIROMIR multitargeting interfering RNA preferentially targeted to viral targets
  • an “activity”, a “biological activity”, or a “functional activity” of a polypeptide or nucleic acid refers to an activity exerted by a polypeptide or nucleic acid molecule as determined in vivo or in vitro, according to standard techniques. Such activities can be a direct activity, such as the RNA interfering activity of an iRNA on a target RNA molecule, or an indirect activity, such as a cellular signaling activity mediated by the RNA interfering activity of an iRNA.
  • Bio system means, material, in a purified or unpurified form, from biological sources, including but not limited to human, animal, plant, insect, microbial, viral or other sources, wherein the system comprises the components required for biologic activity (e.g., inhibition of gene expression).
  • biological system includes, for example, a cell, a virus, a microbe, an organism, an animal, or a plant.
  • a “cell” means an autonomous self-replicating unit that may constitute an organism (in the case of unicellular organisms) or is a sub unit of multicellular organisms in which individual cells may be specialized and/or differentiated for particular functions.
  • a cell can be prokaryotic or eukaryotic, including bacterial cells such as E. coli , fungal cells such as yeast, bird cell, mammalian cells such as cell lines of human, bovine, porcine, monkey, sheep, apes, swine, dog, cat, and rodent origin, and insect cells such as Drosophila and silkworm derived cell lines, or plant cells.
  • the cell can be of somatic or germ line origin, totipotent or hybrid, dividing or non-dividing.
  • the cell can also be derived from or can comprise a gamete or embryo, a stem cell, or a fully differentiated cell. It is further understood that the term “cell” refers not only to the particular subject cell, but also to the progeny or potential progeny of such a cell. Because certain modifications can occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
  • RNA Ribonucleotide
  • oligonucleotides which terms are used interchangeably herein
  • RNA Two major fundamental interactions in RNA are stacking and hydrogen bonding. Both contribute to free-energy changes for associations of oligoribonucleotides.
  • RNA-RNA interactions include the standard Watson-Crick pairing (A opposite U or T, and G opposite C) and the non-Watson-Crick pairing (including but not limited to the interaction through the Hoogsteen edge and/or sugar edge) (see e.g., Leontis et al., 2002, Nucleic Acids Research, 30: 3497-3531).
  • a sequence that is complementary to another sequence is also referred to as the complement of the other.
  • RNAi activity or inhibition of gene expression or formation of double stranded oligonucleotides can be made using methods known in the art (see, e.g., Turner et al., 1987, Cold Spring Harb Symp Quant Biol. 52:123-33; Frier et al., 1986, Proc. Nat. Acad. Sci. USA 83:9373-9377; Turner et al., 1987, J. Am. Chem. Soc. 109:3783-3785).
  • complementarity can be partial, for example where at least one or more nucleic acid bases between strands can pair according to the canonical base pairing rules.
  • sequences 5′-CTGACAATCG-3′,5′-CGAAAGTCAG-3′ are partially complementary (also referred to herein as “incompletely complementary”) to each other.
  • partial complementarity or “partially complementary” as used herein indicates that only a percentage of the contiguous residues of a nucleic acid sequence can form Watson-Crick base pairing with the same number of contiguous residues in a second nucleic acid sequence in an anti-parallel fashion.
  • nucleotides out of a total of 10 nucleotides in the first oligonucleotide forming Watson-Crick base pairing with a second nucleic acid sequence having 10 nucleotides represents 50%, 60%, 70%, 80%, 90%, and 100% complementarity respectively.
  • Complementarity can also be total where each and every nucleic acid base of one strand is capable of forming hydrogen bonds according to the canonical base pairing rules, with a corresponding base in another, antiparallel strand.
  • the sequences 5′-CTGACAATCG-3′ and 5′-CGATTGTCAG-3′ are totally complementary (also referred to herein as “completely complementary”) to each other.
  • complete complementarity or “completely complementary” indicates that all the contiguous residues of a nucleic acid sequence can form Watson-Crick base pairing with the same number of contiguous residues in a second nucleic acid sequence in an anti-parallel fashion.
  • a sequence that is completely complementary to another sequence is also referred to as the complete complement of the other.
  • the two strands would be considered to have no complementarity.
  • at least portions of two antiparallel strands will have no complementarity. In certain embodiments such portions may comprise even a majority of the length of the two strands.
  • strands that are incompletely or partially complementary there may be portions or sections of the strands wherein there are several or even many contiguous bases which are completely complementary to each other, and other portions of the incompletely complementary strands which have less than complete complementarity—i.e. those sections are only partially complementary to each other.
  • the percentage of complementarity between a first nucleotide sequence and a second nucleotide sequence can be evaluated by sequence identity or similarity between the first nucleotide sequence and the complement of the second nucleotide sequence.
  • a nucleotide sequence that is X % complementary to a second nucleotide sequence is X % identical to the complement of the second nucleotide sequence.
  • the “complement of a nucleotide sequence” is completely complementary to the nucleotide sequence, whose sequence is readily deducible from the nucleotide sequence using the rules of Watson-Crick base pairing.
  • Constant or conserved indicates the extent to which a specific sequence is found to be represented in a group of related target sequences, regardless of the genetic context of the specific sequence.
  • Genetic context refers to the flanking sequences that surround a specific identified sequence and that are sufficiently long to enable one of average skill in the art to determine its position within a genome or RNA molecule relative to sequence annotations or other markers in common use.
  • sequence identity or similarity is the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case can be, as determined by the match between strings of such sequences. To determine the percent identity or similarity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence).
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
  • a position in the first sequence is occupied by the same or similar amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical or similar at that position.
  • Two sequences that share 100% sequence identity are identical. In one embodiment, the two sequences are the same length.
  • a non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin et al., (1990), Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin et al., (1993), Proc. Natl. Acad. Sci. USA 90:5873-5877.
  • Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al., (1990), J Mol. Biol. 215:403-410.
  • Gapped BLAST can be utilized as described in Altschul et al., (1997), Nucleic Acids Res. 25:3389-3402.
  • PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules.
  • the default parameters of the respective programs e.g., XBLAST and NBLAST
  • the FASTA method (Atschul et al., (1990), J. Molec. Biol. 215, 403), can also be used.
  • the percent identity between two sequences is determined using the Needleman and Wunsch ( J. Mol. Biol . (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package.
  • the Accelrys GCG GAP program aligns two complete sequences to maximize the number of matches and minimizes the number of gaps.
  • the percent identity between two sequences is determined using the local homology algorithm of Smith and Waterman ( J Mol Biol. 1981, 147(1):195-7), which has been incorporated into the BestFit program in the Accelrys GCG software package.
  • the BestFit program makes an optimal alignment of the best segment of similarity between two sequences. Optimal alignments are found by inserting gaps to maximize the number of matches.
  • nucleotide sequences that share a substantial degree of complementarity will form stable interactions with each other, for example, by matching base pairs.
  • stable interaction indicates that the two nucleotide sequences have sufficient complementarity and have the natural tendency to interact with each other to form a double stranded molecule.
  • Two nucleotide sequences can form stable interaction with each other within a wide range of sequence complementarity. In general, the higher the complementarity the stronger or the more stable the interaction is. Different strengths of interactions, may be required for different processes.
  • the strength of interaction for the purpose of forming a stable nucleotide sequence duplex in vitro may be different from that for the purpose of forming a stable interaction between an iRNA and a binding sequence in vivo.
  • the strength of interaction can be readily determined experimentally or predicted with appropriate software by a person skilled in the art.
  • Hybridization can be used to test whether two polynucleotides are substantially complementary to each other and to measure how stable the interaction is. Polynucleotides that share a sufficient degree of complementarity will hybridize to each other under various hybridization conditions. In one embodiment, polynucleotides that share a high degree of complementarity thus form strong stable interactions and will hybridize to each other under stringent hybridization conditions.
  • Stringent hybridization conditions has the meaning known in the art, as described in Sambrook et al., Molecular Cloning: A Laboratory Manual , Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., (1989).
  • An exemplary stringent hybridization condition comprises hybridization in 6 ⁇ sodium chloride/sodium citrate (SSC) at about 45° C., followed by one or more washes in 0.2 ⁇ SSC and 0.1% SDS at 50-65° C.
  • mismatch refers to a nucleotide of either strand of two interacting strands having no corresponding nucleotide on the corresponding strand or a nucleotide of either strand of two interacting strands having a corresponding nucleotide on the corresponding strand that is non-complementary.
  • a “match” refers to a complementary pairing of nucleotides.
  • the term “expression system” refers to any in vivo or in vitro system that can be used to evaluate the expression of a target RNA molecule and or the RNAi activity of a multitargeting RNA molecule of the invention.
  • the “expression system” comprises one or more target RNA molecules, a multitargeting interfering RNA molecule targeting the target RNA molecules, and a cell or any type of in vitro expression system known to a person skilled in the art that allows expression of the target RNA molecules and RNAi.
  • RNA includes any molecule comprising at least one ribonucleotide residue, including those possessing one or more natural nucleotides of the following bases: adenine, cytosine, guanine, and uracil; abbreviated A, C, G, and U, respectively, modified ribonucleotides, universal base, acyclic nucleotide, abasic nucleotide and non-ribonucleotides.
  • “Ribonucleotide” means a nucleotide with a hydroxyl group at the 2′ position of a p-D-ribo-furanose moiety.
  • non-target transcriptome indicates the transcriptome aside from the targeted RNA molecules.
  • the non-targeted transcriptome is that of the host.
  • the non-targeted transcriptome is the transcriptome of the biological system aside from the given targeted RNA.
  • Modified ribonucleotides include, for example 2′deoxy, 2′deoxy-2′-fluoro, 2′O-methyl, 2′O-methoxyethyl, 4′thio or locked nucleic acid (LNA) ribonucleotides. Also contemplated herein is the use of various types of ribonucleotide analogues, and RNA with internucleotide linkage (backbone) modifications. Modified internucleotide linkages include for example, phosphorothioate-modified, and even inverted linkages (i.e. 3′-3′ or 5′-5′).
  • Preferred ribonucleotide analogues include sugar-modified, and nucleobase-modified ribonucleotides, as well as combinations thereof.
  • the 2′-OH-group is replaced by a substituent selected from H, OR, R, halo, SH, SR, NH 2 , NHR, NR 2 or ON, wherein R is C1-C6 alkyl, alkenyl or alkynyl and halo is F, Cl, Br, or I.
  • the phosphoester group connecting to adjacent ribonucleotides is replaced by a modified group, e.g.
  • nucleobase-modified ribonucleotides i.e. ribonucleotides wherein the naturally-occurring nucleobase is replaced with a non-naturally occurring nucleobase instead, for example, uridines or cytidines modified at the S-position (e.g. 5-(2-amino)propyl uridine, and 5-bromo uridine); adenosines and guanosines modified at the 8-position (e.g.
  • 8-bromo guanosine 8-bromo guanosine
  • deaza nucleotides e.g. 7-deaza-adenosine
  • O- and N-alkylated nucleotides e.g. N6-methyl adenosine
  • universal base refers to nucleotide base analogs that form base pairs with each of the natural DNA/RNA bases with little discrimination between them.
  • Non-limiting examples of universal bases include C-phenyl, C-naphthyl and other aromatic derivatives, inosine, azole carboxamides, and nitroazole derivatives such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole as known in the art (see for example Loakes, 2001, Nucleic Acids Research, 29, 2437-2447).
  • acyclic nucleotide refers to any nucleotide having an acyclic ribose sugar, for example where any of the ribose carbons (C1, C2, C3, C4, or C5), are independently or in combination absent from the nucleotide.
  • the bases thymidine (“T”) and uridine (“U”) are frequently interchangeable depending on the source of the sequence information (DNA or RNA). Therefore, in disclosure of target sequences, seed sequences, candidate seeds, target RNA binding sites, and the like, the base “T” is fully interchangeable with the base “U”.
  • the base “U” cannot be generally substituted with “T” in a functional manner. It is however known in the art that certain occurrences of the base “U” in RNA molecules can be substituted with “T” without substantially deleterious effect on functionality.
  • a “target RNA molecule” or a “pre-selected target RNA molecule” as used herein refers to any RNA molecule whose expression or activity is desired to be modulated, for example decreased, by an interfering RNA molecule of the invention in an expression system.
  • a “target RNA molecule” can be a messenger RNA molecule (mRNA) that encodes a polypeptide of interest.
  • mRNA messenger RNA molecule
  • a messenger RNA molecule typically includes a coding region and non-coding regions preceding (“5′UTR”) and following (“3′UTR”) the coding region.
  • a “target RNA molecule” can also be a non-coding RNA (ncRNA), such as small temporal RNA (stRNA), micro RNA (miRNA), small nuclear RNA (snRNA), short interfering RNA (siRNA), small nucleolar RNA (snoRNA), ribosomal RNA (rRNA), transfer RNA (tRNA) and precursor RNAs thereof.
  • ncRNA non-coding RNA
  • stRNA small temporal RNA
  • miRNA micro RNA
  • snRNA small nuclear RNA
  • siRNA small interfering RNA
  • siRNA small nucleolar RNA
  • rRNA ribosomal RNA
  • tRNA transfer RNA
  • precursor RNAs thereof such as small temporal RNA (stRNA), such as small temporal RNA (stRNA), micro RNA (miRNA), small nuclear RNA (snRNA), short interfering RNA (siRNA), small nucleolar RNA (snoRNA), ribosom
  • the “target RNA molecule” can be a RNA molecule that is endogenous to a biological system, or a RNA molecule that is exogenous to the biological system, such as a RNA molecule of a pathogen, for example a virus, which is present in a cell after infection thereof.
  • a cell containing the target RNA can be derived from or contained in any organism, for example a plant, animal, protozoan, virus, bacterium, or fungus.
  • Non-limiting examples of plants include monocots, dicots, or gymnosperms.
  • Non-limiting examples of animals include vertebrates or invertebrates.
  • Non-limiting examples of fungi include molds or yeasts.
  • a “target RNA molecule” as used herein may include any variants or polymorphism of a desired RNA molecule. Most genes are polymorphic in that a low but nevertheless significant rate of sequence variability occurs in a gene among individuals of the same species. Thus, a RNA molecule may correlate with multiple sequence entries, each of which represents a variant or a polymorphism of the RNA molecule. In designing any gene suppression tool there is the risk that the selected binding sequence(s) used in the computer-based design may contain relatively infrequent alleles. As a result, the active sequence designed might be expected to provide the required benefit in only a small proportion of individuals.
  • SNPs single nucleotide polymorphisms
  • sequences with a target molecule that are known to be highly polymorphic can be avoided in the selection of binding sequences during the bioinformatic screen.
  • a limitless number of sequences available for any particular target may be used in the design stages of an interfering RNA of the invention to make sure that the targeted binding sequence is present in the majority of allelic variants, with the exception of the situation in which targeting of the allelic variant is desired (that is, when the allelic variant itself is implicated in the disease of interest).
  • a “target RNA molecule” comprises at least one targeted binding sequence that is sufficiently complementary to the guide sequence of an interfering RNA molecule of the invention to allow stable interaction of the binding sequence with the guide sequence.
  • the targeted binding sequence can be refined to include any part of the transcript sequence (eg 5′UTR, ORF, 3′UTR) based on the desired effect. For example, translational repression is a frequent mechanism operating in the 3′UTR (i.e. as for microRNA).
  • the targeted binding sequence can include sequences in the 3′ UTR for effective translational repression.
  • target binding sequence shall all mean a portion of a target RNA molecule sequence comprising a seed sequence and the sequence flanking either one or both ends of the seed, said binding sequence predicted to a form stable interaction with one strand of a multitargeting interfering RNA of the invention based on the complementarity between the said strand and the binding sequence.
  • seed or “seed sequence” or “seed region sequence” refers to a sequence of at least about 6 contiguous nucleotides present in a target RNA that is completely complementary to a portion of one strand of an interfering RNA. Although 6 or more contiguous bases are preferred, the expression “about 6” refers to the fact that windows of at least 5 or more contiguous bases or more can provide useful candidates in some cases and can ultimately lead to the design of useful interfering RNAs. Thus, all such seed sequences are contemplated within the scope of the instant invention.
  • RNA interference As used herein, the term “interfering RNA” or “iRNA” is used to indicate single or double stranded RNA molecules that modulate the presence, processing, transcription, translation, or half-life of a target RNA molecule, for example by mediating RNA interference (“RNAi”), in a sequence specific manner.
  • RNA interference or “RNAi” is meant to be equivalent to other terms used to describe sequence specific RNA interference, such as post-transcriptional gene silencing, translational inhibition, or epigenetics. This includes, for example, RISC-mediated degradation or translational repression, as well as transcriptional silencing, altered RNA editing, competition for binding to regulatory proteins, and alterations of mRNA splicing.
  • the interfering RNAs provided herein may exert their functional effect via any of the foregoing mechanisms alone, or in combination with one or more other means of RNA modulation known in the art.
  • the interfering RNAs provided herein can be used to manipulate or alter the genotype or phenotype of an organism or cell, by intervening in cellular processes such as genetic imprinting, transcription, translation, or nucleic acid processing (e.g., transamination, methylation, etc.).
  • interfering RNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi, for example short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically-modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and others.
  • siRNA short interfering RNA
  • dsRNA double-stranded RNA
  • miRNA micro-RNA
  • shRNA short hairpin RNA
  • ptgsRNA post-transcriptional gene silencing RNA
  • the “interfering RNA” can be assembled from two separate oligonucleotides.
  • the “interfering RNA” can also be assembled from a single oligonucleotide, comprising self-complementary regions linked by means of a nucleic acid based or non-nucleic acid-based linker(s).
  • the “interfering RNA” can be a polynucleotide with a duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having self-complementary regions.
  • the “interfering RNA” can also be a single-stranded polynucleotide having one or more loop structures and a stem comprising self-complementary regions (e.g.
  • shRNA short hairpin RNA
  • shRNA short hairpin RNA
  • the polynucleotide can be processed either in vivo or in vitro to generate one or more double stranded interfering RNA molecules capable of mediating RNA inactivation.
  • the cleavage of the self-paired region or regions of the single strand RNA to generate double-stranded RNA can occur in vitro or in vivo, both of which are contemplated for use herein.
  • the “interfering RNA” need not be limited to those molecules containing only RNA, but further encompasses those possessing one or more modified ribonucleotides and non-nucleotides, such as those described supra.
  • interfering RNA includes double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the multitargeting interfering RNA or internally, for example at one or more nucleotides of the RNA.
  • Nucleotides in the RNA molecules of the instant invention can also comprise non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as analogs or analogs of naturally occurring RNA.
  • the interfering RNA of the invention also termed “multitargeting interfering RNA” is an interfering double-stranded RNA, each strand of which can form stable interactions with binding sites present in distinct genetic contexts on one or more target RNA molecules.
  • multitargeting interfering RNA include CODEMIRs, COmputationally-DEsigned, Multi-targeting Interfering RNAs, and VIROMIRs, where the latter multitargeting interfering RNA molecules are preferentially targeted to viral targets.
  • Sequence means the linear order in which monomers occur in a polymer, for example, the order of amino acids in a polypeptide or the order of nucleotides in a polynucleotide.
  • a “subject” as used herein, refers to an organism to which the nucleic acid molecules of the invention can be administered.
  • a subject can be an animal or a plant, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment, or any cell thereof.
  • a “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • a “plasmid” refers to a circular double stranded DNA loop into which additional DNA segments can be inserted.
  • Another type of vector is a viral vector, wherein additional DNA segments can be inserted.
  • Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • certain vectors, expression vectors are capable of directing the expression of genes to which they are operably linked.
  • modulate means any RNA interference mediated regulation of the level and/or biological activity of the RNA molecule. It includes any RNAi-related post-transcriptional gene silencing, such as by cleaving, destabilizing the target RNA molecule or preventing their translation. In one embodiment, the term “modulate” can mean “inhibit,” but the use of the word “modulate” is not limited to this definition.
  • the modulation of the target RNA molecule is determined in a suitable expression system, for example in vivo, in one or more suitable cells, or in an acellular or in vitro expression system such as are known in the art. Routine methods for measuring parameters of the transcription, translation, or other aspects of expression relating to RNA molecules are known in the art, and any such measurements are suitable for use herein.
  • inhibit By “inhibit”, “down-regulate”, “reduce”, or “decrease” or “decreasing” as with respect to a target RNA or its expression it is meant that the expression of the gene or level and/or biological activity of target RNA molecules is reduced below that observed in the absence of the nucleic acid molecules (e.g., multitargeting interfering RNA) of the invention. In one embodiment, inhibition, down-regulation or reduction with a multitargeting interfering RNA molecule is greater than that observed in the presence of an inactive or attenuated molecule.
  • inhibition, down-regulation, or reduction with a multitargeting interfering RNA molecule is greater than that observed in the presence of, for example, multitargeting interfering RNA molecule with scrambled sequence or with mismatches.
  • inhibition, down-regulation, or reduction of gene expression with a nucleic acid molecule of the instant invention is greater in the presence of the nucleic acid molecule than in its absence.
  • “Inhibit”, “down-regulate”, “reduce”, or “decrease” as with respect to a target RNA or its expression encompasses, for example, reduction of the amount or rate of transcription or translation of a target RNA, reduction of the amount or rate of activity of the target RNA, and/or a combination of the foregoing in a selected expression system.
  • a decrease in the total amount of transcription, the rate of transcription, the total amount of translation, or the rate of translation, or even the activity of an encoded gene product are indicative of such a decrease.
  • the “activity” of an RNA refers to any detectable effect the RNA may have in a cell or expression system, including for example, any effect on transcription, such as enhancing or suppressing transcription of itself or another RNA molecule.
  • the measurement of a “decrease” in expression or the determination of the activity of a given R NA can be performed in vitro or in vivo, in any system known or developed for such purposes, or adaptable thereto.
  • the measurement of a “decrease” in expression by a particular interfering RNA is made relative to a control, for example, in which no interfering RNA is used. In some comparative embodiments such measurement is made relative to a control in which some other interfering RNA or combination of interfering RNAs is used.
  • a change such as the decrease is statistically significant based on a generally accepted test of statistical significance.
  • a change such as the decrease is statistically significant based on a generally accepted test of statistical significance.
  • a given RNA need only show an arithmetic decrease in one such in vitro or in vivo assay to be considered to show a “decrease in expression” as used herein.
  • the biological modulating activity of the multitargeting interfering RNA is not limited to, or necessarily reliant on, degradation or translational repression by conventional RISC protein complexes involved in siRNA and microRNA gene-silencing, respectively.
  • short double-stranded and single-stranded RNA have been shown to have other possible sequence-specific roles via alternative mechanisms.
  • short double-stranded RNA (dsRNA) species may act as modulatory effectors of differentiation/cell activity, possibly through binding to regulatory proteins (Kuwabara, T., et al., (2004), Cell, 116: 779-93).
  • dsRNA may lead to the degradation of mRNA through the involvement of AU-rich element (ARE)-binding proteins (Jing, Q., et al., (2005), Cell, 120: 623-34). Further, dsRNA may also induce epigenetic transcriptional silencing (Morris, K. V., et al., (2004) Science, 305: 1289-89). Processing of mRNA can also be altered through A to I editing and modified splicing.
  • ARE AU-rich element
  • “palindrome” or “palindromic sequence” means a nucleic acid sequence that is completely complementary to a second nucleotide sequence that is identical to the nucleic acid sequence, e.g., UGGCCA.
  • the term also includes a nucleic acid molecule comprising of two nucleotide sequences that are palindromic sequences.
  • detectable change refers to any detectable change to a cell or an organism that occurs in response to contact or treatment with a nucleic acid molecule of the invention. Such detectable changes include, but are not limited to, changes in shape, size, proliferation, motility, protein expression or RNA expression or other physical or chemical changes as can be assayed by methods known in the art. The detectable change can also include expression of reporter genes/molecules such as Green Fluorescent Protein (GFP) or various tags that are used to identify an expressed protein or any other cellular component that can be assayed.
  • GFP Green Fluorescent Protein
  • terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal, human, or plant that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes ameliorating or alleviation of the symptoms of the disease or disorder being treated. Methods are known in the art for determining therapeutically effective doses for the instant pharmaceutical composition.
  • prophylactically effective amount refers to that amount of active compound or pharmaceutical agent that inhibits in a subject the onset of a disorder as being sought by a researcher, veterinarian, medical doctor or other clinician.
  • the interfering RNAs known to one of ordinary skill in the art are double-stranded polynucleotide molecules comprising two self-complementary strands which are sense and antisense to the target.
  • the iRNA duplex is usually designed such that the antisense (guide) strand is preferentially loaded into the RISC and guides the RISC-mediated degradation of the target nucleotide sequence following complementary base-pairing.
  • the sense (passenger) strand may be degraded in the process of loading into the RISC complex or soon after by endonucleases to which single stranded RNA is highly sensitive.
  • the relative thermodynamic characteristics of the 5′ termini of the two strands of an interfering RNA determine whether a strand serves the function of a passenger or a guide strand during RNAi.
  • the present invention provides a multitargeting interfering RNA molecule comprising two strands, each of which is designed against a specific target sequence.
  • the iRNA duplex is designed in such a manner that each strand can be loaded into RISC complexes and thus both strands function as “guide” strands. Preferably both strands are loaded to an approximately equal extent into RISC complexes.
  • One strand is at least partially complementary to a first portion of a target RNA binding sequence, which is also referred to as the seed.
  • the other strand comprises a sequence which is at least partially if not completely identical to the seed, this sequence being at least partially complementary to the first portion of a second target RNA binding sequence.
  • the said first and second target binding sequences are present in distinct genetic contexts in at least one pre-selected target RNA molecule. That is, multiple target RNA binding sites may be present on the same target RNA molecule, on separate RNA molecules, or both.
  • the present invention provides a multitargeting interfering RNA molecule comprising Formula (I): 5′-p-XSY-3′ 3′-X′S′Y′-p-5′
  • p consists of a terminal phosphate group that can be present or absent from the 5′-end of either strand.
  • Any terminal phosphate group known to a person skilled in the art can be used.
  • Such phosphate group includes, but is not limited to, monophosphate, diphosphate, triphosphate, cyclic phosphate or to a chemical derivative of phosphate such as a phosphate ester linkage.
  • S consists of a first nucleotide sequence of a length of about 5 to about 20 nucleotides that is completely complementary to a first portion of a first binding sequence
  • S′ consists of a second nucleotide sequence of a length of about 5 to about 20 nucleotides that is completely complementary to a first portion of a second binding sequence, wherein said first and second binding sequences are present in distinct genetic contexts in at least one pre-selected target RNA molecule, and wherein S and S′ are at least substantially complementary to each other but are not palindromic.
  • S and S′ each has a length of, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides that are at least partially, preferably completely, complementary to the first portion of the at least two binding sequences.
  • S is completely complementary to a sequence present in one or more pre-selected target RNA molecules.
  • S′ is completely complementary to a sequence present in one or more pre-selected target RNA molecules.
  • S and S′ are completely complementary to each other.
  • S is partially complementary to a first portion of a binding sequence present in one or more pre-selected target RNA molecules, such as 6 of 7, 7 of 8, 8 of 9, 9 of 10, 10 of 11, 11 of 12, 12 of 13, 13 of 14, 14 of 15, or 15 of 16 consecutive nucleotides of S are completely complementary to the first portion of at least one target RNA binding sequence.
  • S and the first portion of the distinct binding sequences have lesser overall complementarity such as 10 of 12, 11 of 13, 12 of 14, 13 of 15, or 14 of 16 nucleotides of complete complementarity.
  • S′ is partially complementary to a first portion of a second binding site.
  • the remaining sequence of the two strands of the multitargeting interfering RNA (X,X′, Y and Y′) in Formula (I) is independently absent or consists of a nucleotide sequence. In particular embodiments, they are developed so as to generate further binding to the target RNA sites.
  • the sequences of X and Y′ are at least partially complementary to the second portions of the first and second target RNA binding sequences, respectively.
  • the sequences X′ and Y are completely complementary to X and Y′, respectively, such that XSY and Y′S′X′ are completely complementary.
  • X′ and Y are incompletely complementary with X and Y′, respectively such that XSY and Y′S′X′ are incompletely complementary. This may be required, for example, in situations in which the loading bias of the interfering RNA duplex needs to be altered through the use of mismatches in the extremity with the higher hybridization energy.
  • the sequences X and Y′ are designed so as to maximize binding of XS and Y′S′ to the first and second portions of a plurality of target RNA binding sites.
  • the plurality of target sequences e.g. viral isolates
  • identity consensus sequences can be generated by hand by examining the alignments of the target RNA sequences.
  • all possible base sequences or a subset of putative XS and Y′S′ sequences can be generated by computer algorithm.
  • Each putative XS and Y′S′ sequence is then hybridized in silico using RNAhybrid or a similar program known to one skilled in the art. Those putative sequences that are predicted to best bind the corresponding first and second portions of the target RNA binding sites are then prioritized for the next design phase, which includes filtering out putative sequences that have unfavorable characteristics such as more than 4 contiguous C or G bases.
  • the sequences of Y and X′ are then designed such that they are at least partially complementary to Y′ and X, respectively.
  • Overhangs if required may simply be the addition to X′ and Y of UU, dTdT or any other base or modified base.
  • the bases of the overhangs are selected so as to further increase the predicted binding of XSY and Y′S′X′ to their respective RNA targets. Overhangs may be 1, 2, 3, 4 or 5 bases as required.
  • a preferred embodiment is one in which the two strands of the duplex independently have either partial or complete complementarity to their corresponding at least one target sequence and the two strands are completely complementary to one another, excepting the overhangs when present.
  • Another embodiment of the invention is one in which each of the two strands of the duplex independently have either partial or complete complementary to their corresponding at least one target sequence and the two strands are incompletely complementary to one another. Both strands can be modified and refined to enhance some aspect of the function of the interfering RNA molecule of the invention.
  • interfering RNA can further comprise one or more 5′ terminal phosphate group, such as a 5′-phosphate or 5′,3′-diphosphate. These may be of use to improve cell uptake, stability, tissue targeting or any combination thereof.
  • X consists of a nucleotide sequence that is at least partially complementary to a second portion of the first binding sequence, said second portion is adjacent to and connected with the 3′-end of said first portion of the first binding sequence, and wherein X′ is substantially complementary to X.
  • X and X′ are completely complementary to each other.
  • X is completely complementary to the second portion of the first binding sequence.
  • Y′ consists of a nucleotide sequence that is at least partially complementary to a second portion of the second binding sequence, said second portion is adjacent to and connected with the 3′-end of said first portion of the second binding sequence, and wherein Y is substantially complementary to Y′.
  • Y and Y′ are completely complementary to each other.
  • Y′ is completely complementary to the second portion of the second binding sequence.
  • XSY is at least partially complementary to the first binding sequence to allow stable interaction of XSY with the first binding sequence
  • Y′S′X′ is at least partially complementary to the second binding sequence to allow stable interaction with the second binding sequence
  • XSY and Y′S′X′ are at least partially complementary to each other to allow formation of a stable iRNA duplex.
  • XSY is completely complementary to the first binding sequence.
  • Y′S′X′ is completely complementary to the second binding sequence.
  • XSY and Y′S′X′ are completely complementary to each other.
  • each strand of a multitargeting interfering RNA molecule of the invention is independently about 17 to about 25 nucleotides in length, in specific embodiments about 17, 18, 19, 20, 21, 22, 23, 24, and 25 nucleotides in length.
  • Using shorter length interfering RNA molecules without the need for the generation of multiple active sequences through processing of RNA by enzymes such as Dicer and RNaseIII, provides advantages, for example, in reduction of cost, manufacturing, and chance of off-target effects.
  • the interaction between the two strands can be adjusted to improve loading of both strands into the cellular RISC complex (Khvorova et al. (2003) Cell, 115: 209-16; Schwarz et al. (2003) Cell, 115: 199-208), or to otherwise improve the functional aspects of the interfering RNA.
  • the skilled artisan will appreciate that there are routine methods for altering the strength and other properties of the base paired strands through the addition, deletion, or substitution of one or more bases in either strand of the synthetic duplex.
  • these strategies can be applied to the design of the extremities of the duplex to ensure that the predicted thermodynamics of the duplex are conducive to the loading of the desired strand. These strategies are well known to persons skilled in the art.
  • a single-stranded RNA molecule comprises, for example, a hairpin loop or similar secondary structure that allows the molecule to self-pair to form at least a region of double-stranded nucleic acid of Formula (I).
  • RNA molecules provide certain advantages for use in therapeutic applications.
  • overhangs for example of 1-5 nucleotides, are present at either or both termini.
  • the overhangs are 2 or 3 bases in length.
  • Presently preferred overhangs include 3′-terminus UU overhangs (3′-UU) in certain embodiments.
  • Other overhangs exemplified for use herein include, but are not limited to, 3′-AA, 3′-CA, 3′-AU, 3′-UC, 3′-CU, 3′-UG, 3′-CC, 3′-UA, 3′-U, and 3′-A.
  • Still other either 5′-, or more preferably 3′-, overhangs of various lengths and compositions are contemplated for use herein on the RNA molecules provided.
  • the multitargeting interfering RNA molecule of the invention comprises one or more terminal overhangs, for example, an overhang consisting 1 to 5 nucleotides.
  • the multitargeting interfering RNA molecule of the invention comprises at least one modified ribonucleotide, such as one 2′-O-methyl ribosyl substitution.
  • At least one target RNA molecule is an mRNA. More specifically, in some embodiments at least one target encodes a receptor, cytokine, transcription factor, regulatory protein, signaling protein, cytoskeletal protein, transporter, enzyme, hormone, or antigen. As such, the potential range of protein targets in the cell is not limited, however the skilled artisan will appreciate that certain targets are more likely to be of value in a particular disease state or process. In addition, the skilled artisan will appreciate that target RNA molecules, whether coding or regulatory, originating from a pathogen (e.g. a virus) are useful with the multitargeting interfering RNAs and methods provided herein.
  • a pathogen e.g. a virus
  • At least one of the binding sequences is in the 3′ UTR of an mRNA.
  • the inclusion of one target or more targets does not preclude the use of, or intention for, a particular interfering RNA to target another selected target. Such targeting of any additional RNA target molecules may result in less, equal, or greater effect in an expression system.
  • the multitargeting interfering RNAs of the instant invention are preferably screened for off-target effects, especially those that are likely. For example, reviewing the potential binding to the entire transcriptome, or as much of it as is known at the time provides a useful approach to such screening. For example, where a genome has been completely sequenced, the skilled artisan will appreciate that the entire transcriptome can be conveniently screened for likely off-target effects.
  • tissue-specific transcriptomes eg retina for ocular applications
  • non-target transcripts that are identified through bioinformatic approaches from the complete transcriptome may actually not be present in the tissue into which the multitargeting interfering RNA is applied.
  • the two strands of a multitargeting interfering RNA of the invention form stable interaction with at least two distinct targeted binding sequences present in distinct genetic contexts on a single target RNA molecule, and thus modulates the expression or activity of the RNA molecule.
  • Targeting multiple binding sites on a single target RNA molecule with a single iRNA provides more effective RNAi of the target RNA molecule. This approach is particularly useful for the modulation of virus gene expression where the mutation rate is high.
  • the two strands of a multitargeting interfering RNA of the invention form stable interaction with at least two binding sequences present in distinct genetic contexts on multiple pre-selected target RNA molecules, and thus modulates the expression or activity of multiple pre-selected target RNA molecules.
  • Targeting multiple target RNA molecules with a single iRNA represents an alternative to the prototypical one drug one target approach. In considering the complexity of biological systems, designing a drug selective for multiple targets will lead to new and more effective medications for a variety of diseases and disorders.
  • RNA molecules that are involved in a disease or disorder of a biological system are pre-selected and targeted by a multitargeting interfering RNA molecule of the invention.
  • the biological system can be, for example, a plant, or an animal such as a rat, a mouse, a dog, a pig, a monkey, and a human.
  • the pre-selected target RNA molecules can, for example, encode a protein of a class selected from the group consisting of receptors, cytokines, transcription factors, regulatory proteins, signaling proteins, cytoskeletal proteins, transporters, enzymes, hormones, and antigens.
  • the pre-selected target RNA molecules can, for example, encode a protein selected from the group consisting of ICAM-1, VEGF-A, MCP-1, IL-8, VEGF-B, IGF-1, Gluc6p, Inppl1, bFGF, PlGF, VEGF-C, VEGF-D, ⁇ -catenin, ⁇ -ras-B, ⁇ -ras-A, EGFR, and TNF alpha.
  • the multitargeting interfering RNA molecule of the invention can, for example, modulate expression of any combination of ICAM-1, VEGF-B, VEGF-C, VEGF-D, IL-8, bFGF, PlGF, MCP-1 and IGF-1, any combination of ICAM-1, VEGF-A and IGF-1, any combination of ⁇ -catenin, ⁇ -ras, and EGFR, both ICAM-1 and VEGF-A, or both Gluc6p and Inppl1, in a biological system, such as an animal.
  • the pre-selected target RNA molecule can also be a viral RNA, including a viral RNA encoding a protein essential for the virus.
  • Such essential proteins can, for example, be involved in the replication, transcription, translation, or packaging activity of the virus.
  • Exemplary essential proteins for a HIV virus are GAG, POL, VIF, VPR, TAT, NEF, REV, VPU and ENV, all of which can be a pre-selected target molecule of the invention.
  • the multitargeting interfering RNA of the invention can be used to modulate viral RNA from, including but not limited to, a human immunodeficiency virus (HIV), a hepatitis C virus (HCV), an influenza virus, a rhinovirus, and a severe acute respiratory syndrome (SARS) virus or a combination thereof.
  • HIV human immunodeficiency virus
  • HCV hepatitis C virus
  • influenza virus influenza virus
  • rhinovirus a severe acute respiratory syndrome (SARS) virus or a combination thereof.
  • SARS severe acute respiratory syndrome
  • the multitargeting interfering RNA of the invention are designed to target one or more target RNA molecules in a first biological system and one or more target molecules in a second biological system that is infectious to the first biological system.
  • the multitargeting interfering RNA of the invention are designed to target one or more host RNA molecules and one or more RNA molecules of a virus or a pathogen for the host.
  • the viral RNA is HCV or HIV and the host target RNA includes, but is not limited to, TNFalpha, LEDGF(p75), BAF, CCR5, CXCR4, furin, NFkB or STAT1.
  • RNA molecules are provided in the Examples that are functional against specific targets.
  • CODEMIRs and/or VIROMIRs are useful for decreasing expression of RNAs, for example, their intended target RNA molecules and data supporting the activity are also provided herein in the working examples.
  • Such molecules can target multiple sites on a single RNA or multiple sites on two or more RNAs and are useful to decrease the expression of such one or preferably two or more such targeted RNAs in an expression system.
  • a given multitargeting interfering RNA will be more effective at modulating expression of one of several target RNAs than another.
  • the multitargeting interfering RNA will similarly affect all targets in one or more expression systems.
  • Various factors can be responsible for causing variations in silencing or RNAi efficiency: (i) asymmetry of assembly of the RISC causing one strand to enter more efficiently into the RISC than the other strand; (ii) inaccessibility of the targeted segment on the target RNA molecule; (iii) a high degree of off-target activity by the interfering RNA; (iv) sequence-dependent variations for natural processing of RNA, and (v) the balance of the structural and kinetic effects described in (i) to (iv).
  • Another general aspect of the invention is a method for designing a multitargeting interfering RNA.
  • the method of the invention includes various means leading to a multitargeting interfering RNA that effectively target distinct binding sequences present in distinct genetic contexts in one or more pre-selected target RNA molecules.
  • a multitargeting interfering RNA can be designed by visual or computational inspection of the sequences of the target molecules, for example, by comparing target sequences and their complements and identifying sequences of length n which occur in both the target sequence and the complement of the target sequence sets.
  • a multitargeting interfering RNA can be designed by visual or computational inspection of the sequences of the target molecules to find occurrences of the sequence of length n and of its complete complement within the set of target sequences.
  • all possible sequences of a pre-selected length n can be generated by virtue of each permutation possible for each nucleotide position to a given length (4 n ) and then examining for their occurrence in the pre-selected nucleotide sequences and their complements.
  • all possible sequences of a pre-selected length n and their complete complements can be generated by virtue of each permutation possible for each nucleotide position to a given length (4 n ) and then examining for their occurrence in the pre-selected nucleotide sequences.
  • a multitargeting interfering RNA when there is a pluarilty of target sequences, can be designed by visual or computational inspection of the sequences of the target molecules, for example, by aligning sequences and visually or computationally finding consensus target sequences for the design.
  • each strand be capable of modulating expression of its intended target (i.e. each strand is “active” against its target RNA, e.g. by having at least partial complementarity thereto) while simultaneously requiring that each of the strands is at least sufficiently complementary to the other that a duplex can form.
  • each strand is “active” against its target RNA, e.g. by having at least partial complementarity thereto) while simultaneously requiring that each of the strands is at least sufficiently complementary to the other that a duplex can form.
  • there is no strand which is solely a guide strand or solely a passenger strand because each strand serves as both guide strand and passenger strand.
  • Such molecules can be designed as single strands with hairpin structures that can, for example, be processed in vivo to become a duplex consisting of two separate strands.
  • the invention provides a method for designing a multitargeting interfering RNA molecule, comprising the steps of:
  • the method further comprise repeating steps g) to k) for each seed of length n selected from the group of candidate seeds in step f).
  • the method further comprises the step of repeating steps c) to k) for another desired seed length.
  • the number of candidate seeds will increase as the length of the seed is decreased.
  • finding a candidate seed present in at least one of the selected RNA sequences and in at least one complement of the selected RNA sequences is an alternative to finding the candidate seed and its complete complement in the selected RNA sequences.
  • RNA molecule of the invention Often the preference for designing a multitargeting interfering RNA molecule of the invention involves: firstly, identifying the seed and its complement, which occur in different genetic contexts; secondly, determining XS and Y′S′ so as to bind to their respective target RNA sequences, and then determining XSY and Y′S′X′ wherein Y is the complement of Y′ and X′ is the complement of X.
  • XS may be determined as the complement of the seed (equates to S) together with the complement of a portion of the 3′ flanking sequence of the seed (equates to X).
  • Y′S′ may be determined as the complement of the complement of the seed (equates to S′) together with the complement of a portion of the 3′ flanking sequence of the complement of the seed (equates to Y′).
  • the plurality of 3′ flanking sequences may be examined to yield consensus 3′ flanking sequences.
  • X and/or Y′ can then be determined as the complements of these consensus 3′ flanking sequences. Further modifications can be made to the molecule as described in this specification.
  • Preferred target RNA molecules are strategically selected molecules, for example viral or host RNAs involved in disease processes, viral genomes, particularly those of clinical significance, and the like.
  • a detailed discussion of target RNA is provided above and applies equally to this and other aspects of the invention, as if set out in its entirety here. The basis for the selection of a target RNA molecule will be appreciated by those of skill in the art.
  • Preferred target RNAs are those involved in diseases or disorders one wishes to control by the administration of the multitargeting interfering RNA.
  • the step of obtaining the sequences for the selected target is conducted by obtaining sequences from publicly available sources, such as the databases provided by the National Center For Biotechnology Information (NCBI) (through the National Institutes of Health (NIH) in the United States), the European Molecular Biology Laboratories (through the European Bioinformatics Institute throughout Europe) available on the World-Wide Web, or proprietary sources such as fee-based databases and the like. Sequences can also be obtained by direct determination. This may be desirable where a clinical isolate or an unknown gene is involved or of interest, for example, in a disease process. Either complete or incomplete sequences of a target RNA molecule can be used for the design of multitargeting interfering RNA of the invention.
  • a plurality of independent target nucleotide sequences are obtained in step b) for each of one or more target RNA molecules selected in step a).
  • the databases described above frequently have multiple sequences available for particular targets. This is especially true where genetic variation is naturally higher, for example with viral sequences.
  • the plurality of target nucleotide sequences represents strain variation, allelic variation, mutation, or multiple species. The number of such a plurality of sequences may range from several or a low multiple, to numerous—for example dozens or even hundreds or thousands of sequences for a given target. It is especially possible to have such numbers of sequences when working with viral sequences.
  • sequences chosen can be further limited based on additional desirable or undesirable features such as areas of low sequence complexity, poor sequence quality, or those that contain artifacts relating to cloning or sequencing such as inclusion of vector-related sequences. Furthermore, regions with extensive inaccessible secondary structure could be filtered out at this stage. Indeed, Luo and Chang have demonstrated that siRNA targeting accessible regions of mRNA structure such as loops were more likely to be effective than those aligned with stems (Luo & Chang, (2004), Biochem. Biophys. Res. Commun., 318: 303-10). The sequences chosen, however, need not be limited to 3′UTR sequences or regions of low secondary structure.
  • the step of selecting a length of n nucleotide bases for a seed sequence is preferably an iterative process that does not require any particular basis or logic at first glance—i.e. the starting seed length may be any number of bases above about 6.
  • the starting seed length may be any number of bases above about 6.
  • the longer the length that is chosen for a seed the less likely that it and its complete complement will appear in the at least one target RNA, e.g. in a target RNA sequence.
  • the shorter the seed sequence length the more frequently it will occur as would be expected.
  • an iterative process is used to find the preferred sequences for candidate seeds as described below.
  • another value e.g. n+1, n ⁇ 1 will be used and the process can be repeated to identify candidate seed sequences of length n+1, n ⁇ 1 and so on.
  • seed candidates include sequences of a particularly desired or selected length each of which and its complete complement are not palindromic, and wherein the candidate seed occurs at least once in one or more of the nucleotide sequences obtained in step b), and its complete complement occurs at least once in one or more of the nucleotide sequences obtained in step b).
  • the candidate seeds are preferably generated by computer, for example by moving stepwise along a target sequence with a “window” (expressed in terms of a fixed number of contiguous nucleotides) of the desired or selected seed length.
  • each step is a single base progression, thus generating a “moving window” of selected length through which each target sequence is sequentially viewed.
  • Other step distances are contemplated, however, the skilled artisan will appreciate that only a step of one nucleotide will allow the generation of all possible seeds sequences.
  • a collection of candidate seeds of the length n can be obtained by the steps of:
  • a collection of candidate seeds of the length n can be obtained by the steps of:
  • the method further comprises the step of discarding candidate seed sequences for which either the seed or its complete complement do not occur with at least a predetermined minimum frequency in the target nucleotide sequences.
  • the method ultimately chosen will include one or more of these steps, or all of them as needed.
  • the method further comprises the step of discarding any candidate seed sequence that: is composed of only a single base, is composed only of A and U, has a consecutive string of 5 or more C or 5 or more G, is predicted to occur with unacceptable frequency in the non-target transcriptome of interest; is predicted to have a propensity to undesirably modulate the expression or activity of one or more cellular component (eg. to undesirably activate a cellular sensor of foreign nucleic acid), or any combination thereof.
  • Seeds then are selected from the pool of candidate sequences as the ones where the seed is present in one genetic context, and its complete complement is present in a different genetic context in the at least one pre-selected target sequence. Genetic contexts are determined by collecting, for each occurrence of the candidate seed sequence, a desired amount of the 5′ and 3′ flanking sequence. The genetic context of the complement of the seed is determined in a similar fashion.
  • a “consensus target sequence” is selected for one or both strands of the interfering RNA.
  • Consensus target sequence does not suggest that there is only one best sequence approximating multiple binding sequences on target molecule(s), rather a population of one or more alternative sequences may all be consensus target sequences.
  • a first consensus target sequence for the first strand of the iRNA comprises a seed sequence and a consensus 3′-flanking sequence to the seed in at least one of the chosen sequences for the target molecules.
  • a second consensus target sequence for the second strand of the iRNA comprises the complete complement of the seed and a consensus 3′ flanking sequence to the complete complement of the seed in at least one of the chosen sequences for the target molecules.
  • the “consensus 3′ flanking sequence” of the seed is readily derived by visual inspection, or through the use of bioinformatic tools or calculations, from the examination of the genetic context of each occurrence of the seed sequence in the sequences of the target molecules. While the seed portion of the consensus target sequence has complete identity to a corresponding portion in each of the targeted binding sites, the consensus 3′ flanking sequence need not be completely identical, but can be identical, to the sequence/s flanking the 3′ end of the seed of one or more of the target sequences. Likewise, the “consensus 3′ flanking sequence” of the complement of the seed is readily derived by visual inspection, or through the use of bioinformatic tools or calculations, from the examination of the genetic context of each occurrence of the complement of the seed.
  • the consensus 3′ flanking sequence need not be completely identical, but can be identical, to the sequencers flanking the 3′ end of the complement of the seed.
  • the consensus target sequence does not include any sequence that is predicted to have a propensity to undesirably modulate the expression or activity of one or more cellular component.
  • Consensus target sequences may be determined by eye or by algorithm.
  • a computer algorithm can be used to score all possible permutations of paired nucleotides in the positions in which the sequences are different. This is particularly useful when the target sequences have some identity beyond the seed, but for which an alignment by eye proves difficult.
  • This method can be used to determine the consensus target sequence/s, or alternatively, directly design the strands of the candidate multitargeting interfering RNA.
  • One alternative approach that is particularly useful when a large number of target sequences need to be considered is to generate all possible permutations of the extension from the seed to a required length, and/or the complete complement of the seed to a required length, thereby generating the putative Y′S′ and/or XS of Formula (I) and hybridizing each putative XS and Y′S′ against the target sequences of interest in silico to determine those which demonstrate the most favorable properties in terms of hybridization to the target.
  • Sequences demonstrating strong binding are of particular interest for the multitargeting interfering RNA.
  • the candidate XS and Y′S′ are then prioritized for testing not only on this basis but also taking into account other features that may be important for the functionality of the multitargeting interfering RNA (by, for example, use of appropriate penalty terms).
  • the addition of one or two nucleotides to the 5′ end of the putative XS or Y′S′ that are not complementary to their respective target sequences is considered. This is particularly relevant when an otherwise useful XS or Y′S′ is G/C rich at the 5′ end and this is predicted to disfavor loading relative to the other strand.
  • the addition of one or two A/U nucleotides to the 5′ extremity of the G/C rich XS or Y′S′ will most likely promote balanced loading, which is required for optimal activity of the multitargeting RNA.
  • substitution of U for C in the corresponding strand will at least partially rectify strand loading when there is a G near the 5′ terminus of the XS or Y′S′ by virtue of the wobble base pairing present between U and G, which is weaker than the pairing between C and G.
  • substitutions with chemically modified bases such as 2′F, 2′-O-methyl and LNA modified ribonucleotides increase the energy of hybridization of nucleotides with matching bases. Therefore, the alternative strategy of strengthening the hybridization of the duplex at the thermodynamically weaker end with chemically modified bases is also envisaged in this invention.
  • DNA sequences with stretches of contiguous guanosines are known to produce additional effects not related to targeting of mRNA.
  • RNA DNA sequences with stretches of contiguous guanosines are known to produce additional effects not related to targeting of mRNA.
  • most manufacturers recommend not selecting dsRNA duplexes containing long runs of G for their experiments. It was found in this invention that greater than 4 consecutive G greatly reduced the activity of the corresponding CODEMIR (data not shown). Therefore, many seeds could be eliminated if a requirement for 5 or more C is applied.
  • One skilled in the art will recognize that the presence of 5 or more Cs in a seed will correspond to 5 or more Gs in the completely complementary RNA molecule of the invention.
  • the method further comprises the step of discarding any consensus target sequence that: is composed of only a single base, is composed only of A and U, has a consecutive string of 5 or more bases which are C, is predicted to occur with unacceptable frequency in the non-target transcriptome of interest, is predicted to have a propensity to undesirably modulate the expression or activity of one or more cellular component, or any combination thereof.
  • Scanning the consensus target sequences against a transcriptome of interest for prediction of off-target effects, and eliminating any sequence predicted to have unacceptable off-target effects on a transcriptome of interest are also useful ways of reducing the number of consensus target sequences, and any of the foregoing may be added as a step in the process.
  • Any undesirable properties for a therapeutic RNA can be used as a basis on which to discard candidate seed sequences, consensus binding sites or proposed multitargeting interfering RNA.
  • consensus target sequences are intermediates in the design of a multitargeting interfering RNA of the invention.
  • the consensus target sequences are used to generate the sequences for the first and the second strand of a multitargeting interfering RNA of the invention.
  • the first strand sequence is designed to comprise the first consensus target sequence and a complement of the consensus 3′ flanking sequence of the second consensus target sequence, which is adjacent to and connected with the 5′-end of the first consensus target sequence.
  • the first strand is designed by extending the first consensus target sequence in the 5′ direction with a complete complement of consensus 3′ flanking sequence of the second consensus target sequence.
  • the second strand sequence is designed to comprise the second consensus target sequence and a complement of the consensus 3′ flanking sequence of the first consensus target sequence, which is adjacent to and connected with the 5′-end of the second consensus target sequence.
  • the second strand is designed by extending the second consensus target sequence in the 5′ direction with a complete complement of consensus 3′ flanking sequence of the first consensus target sequence.
  • Hybridization is typically examined from a thermodynamic perspective using RNAhybrid software (Rehmsmeier et al., 2004, RNA, 10: 1507-17) or similar algorithm.
  • X and Y′ in Formula (I) are completely complementary to their respective target sites.
  • the loading bias needs to be reduced by either producing mismatches in either X′ or Y, depending on the thermodynamic balance.
  • several chemical modifications eg LNA, 2′O-methyl and 2′F can be introduced into the “weak” end of the duplex to improve loading balance.
  • varying the length of the overhang may be used to control the loading balance of the two strands of the duplex.
  • the multitargeting interfering RNA is designed such that there is no loading bias, so that both strands can load equally.
  • RNAs can optionally be added, individually or in combination, to further the rational process of designing the RNAs—such as to reduce the number of sequences unlikely to work for the intended purpose, to increase the effectiveness of the RNAs, to reduce off target effects and the like. Many of these steps can be automated, or require only a limited amount of input from an operator, though the use of bioinformatic computer systems, which as the skilled artisan will appreciate, will facilitate the methods.
  • the designed multitargeting interfering RNA molecule can be modified, for example, i) to improve actual or predicted loading of the strands of the multitargeting interfering RNA molecule into the RNA induced silencing complex (RISC); ii) to increase or decrease the modulation of the expression of at least one target RNA molecule; iii) to decrease stress or inflammatory response when the multitargeting interfering RNA molecule is administered into a subject; iv) to alter half-life in an expression system; or v) any combination of i) to iv).
  • RISC RNA induced silencing complex
  • the modifying step comprises one or more of altering, deleting, or introducing one or more nucleotide bases to create at least one mismatched base pair, wobble base pair, or terminal overhang, or to increase RISC mediated processing.
  • Techniques for doing so are known in the art.
  • the modifications are at least initially performed in silico, and the effects of such modifications can be readily tested against experimental parameters to determine which offer improved properties of the interfering RNA products.
  • the methods, through to the step of actually making an RNA are conducted entirely in silico, or by visual inspection and determination.
  • the method further comprises the step of choosing a new value for the seed length, n, and repeating each of the remaining steps. It is clear that the method can be iterative and the benefits of computers for such purposes are well known.
  • Screens that can be considered for the high throughput assessment of candidates include reporter assays, multiplexed ELISAs, viral replicon systems, dot-blot assays, RT-PCR etc.
  • Candidate multitargeting interfering RNA are routinely synthesized as double-stranded RNA molecules with 19 bp of complementarity and 3′ two nucleotide overhangs.
  • the overhang can be any nucleotides or analogs thereof, such as, for example, dTdT or UU.
  • other types and lengths of overhangs could also be considered, as could “blunt-ended” duplexes.
  • the overhangs are incorporated a priori into the design by having Y and X′ being longer than the corresponding X and Y′ by the length of the required overhangs.
  • multiple multitargeting interfering RNAs can be co-expressed by several strategies, including but not limited to, expression of individual multitargeting interfering RNAs from multiple expression vectors (plasmid or viral), expression from multiple expression cassettes contained within a single vector, with each expression cassette containing a promoter, a single multitargeting interfering RNA and terminator.
  • Multiple multitargeting interfering RNAs can also be generated through a single polycistronic transcript, which contains a series of multitargeting interfering RNAs.
  • the multitargeting interfering RNAs can be expressed sequentially (sense/intervening loop/antisense) or expressed with the sense sequence of each multitargeting interfering RNA sequentially linked 5′ to 3′, joined directly or with intervening loop/spacer sequence, followed by the antisense sequence of each multitargeting interfering RNAs sequentially linked 5′ to 3′.
  • multitargeting interfering RNA are typically tested in cell culture using an appropriate cell line representative of the targeted tissue.
  • the specific conditions used are outlined in the specific examples.
  • Multitargeting interfering RNA that lead to reduction in target RNA expression can then be studied further.
  • semi-quantitative RT-PCR for the target RNA may be performed to establish whether modulation of expression of a target RNA is likely to be mediated by degradation.
  • cells are transfected with the multitargeting interfering RNA at a concentration of 5-40 nM in the culture medium and after 48 hours, are washed, trypsinized and harvested for total RNA using a RNeasy kit (Qiagen).
  • RT-PCR is then performed using primer sets specific for the target RNAs.
  • Proteomic and microarray experiments may be used to assess off-target effects.
  • analysis of markers of IFN-response eg STAT1, IFNb, IL-8, phosphoEIF etc. can be performed on treated cells.
  • the candidate multitargeting interfering RNA are tested for non-specific toxic effects by, for example, direct assays of cell toxicity.
  • cytotoxicity is the desired outcome and may reflect the successful repression of key oncogenic signaling pathways.
  • Multitargeting interfering RNA are additionally assessed for their ability to repress the production of specific target proteins. Multitargeting interfering RNA demonstrating efficacy in this respect are then assessed for additional evidence of off-target effects, including arrest of non-target protein production and activation of Protein Kinase R (PKR) mediated responses.
  • PKA Protein Kinase R
  • the RNA molecule may be expressed from transcription units inserted into vectors.
  • the vector may be a recombinant DNA or RNA vector, and includes DNA plasmids or viral vectors.
  • the multitargeting interfering RNA molecule expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, lentivirus or alphavirus.
  • the vector is an expression vector suitable for expression in a mammalian cell.
  • Suitable routes of administration of the pharmaceutical composition of the present invention may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, intravenous and subcutaneous injections.
  • the pharmaceutical composition may be administered in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a target organ or tissue, such as intramedullary, intrathecal, direct intraventricular, intraperitoneal, or intraocular injections, often in a depot or sustained release formulation.
  • a target organ or tissue such as intramedullary, intrathecal, direct intraventricular, intraperitoneal, or intraocular injections, often in a depot or sustained release formulation.
  • Intravesicular instillation and intranasal/inhalation delivery are other possible means of local administration as is direct application to the skin or affected area. Ex vivo applications are also envisaged.
  • the pharmaceutical composition of the present invention may be delivered in a targeted delivery system, for example, in a liposome coated with target cell-specific antibody.
  • the liposomes will be targeted to and taken up selectively by the target cell.
  • Other delivery strategies include, but are not limited to, dendrimers, polymers, nanoparticles and ligand conjugates of the RNA.
  • the multitargeting interfering RNA molecule of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues.
  • the nucleic acid or nucleic acid complexes can be locally administered to relevant tissues ex vivo, or in vivo through injection, infusion pump or stent, with or without their incorporation in biopolymers.
  • the invention provides biological systems containing one or more multitargeting interfering RNA molecule of this invention.
  • the biological system can be, for example, a virus, a microbe, a plant, an animal, or a cell.
  • the invention also provides a vector comprising a nucleotide sequence that encodes the multitargeting interfering RNA molecule of the invention.
  • the vector is viral, for example, derived from a virus selected from the group consisting of an adeno-associated virus, a retrovirus, an adenovirus, a lentivirus, and an alphavirus.
  • the multitargeting interfering RNA can be a short hairpin RNA molecule, which can be expressed from a vector of the invention.
  • the invention further provides a pharmaceutical composition comprising a multitargeting interfering RNA molecule of the invention and an acceptable carrier.
  • the pharmaceutical composition comprises a vector for a multitargeting interfering RNA molecule of the invention.
  • the present invention provides a method of inducing RNA interference in a biological system, which comprises the step of introducing a multitargeting interfering RNA molecule of the invention into the biological system.
  • the invention further comprises a method of treating a subject, comprising the step of administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a multitargeting interfering RNA molecule of the invention.
  • the invention also provides a method of inhibiting the onset of a disease or condition in a subject, comprising administering to said subject a prophylactically effective amount of a pharmaceutical composition comprising a multitargeting interfering RNA molecule of the invention. Methods are known in the art for determining therapeutically and prophylactically effective doses for the instant pharmaceutical composition.
  • compositions and methods exemplified herein are of use in the treatment of complex multigenic diseases in which single gene-specific therapeutics may be at a disadvantage because of the multiple redundancies in pathophysiologic signaling pathways.
  • a conscious and calculated approach is provided in which key signaling proteins/pathways can be simultaneously targeted with a single agent to generate greatly increased therapeutic potential.
  • the targets of interest may be at least partially controlled by a common “master regulator”. This is usually a transcription factor.
  • a transcription factor For example, down-regulation of IL-8 and MCP-1 might be achievable through targeting the nuclear factor NFkappaB.
  • this pathway is also involved in the survival of Retinal Pigmented Epithelial cells (RPE) in times of stress and the down regulation of such a cell-survival factor would likely lead to increased death of RPE in diseased eyes. Therefore, the novel approach disclosed herein has the advantage of being amenable to the modulation of specific targets of interest without having to identify suitable target “upstream” pleiotropic controllers.
  • RNA molecules active against several key pathways may derive synergistic activity against cells reliant on several of these targeted pathways.
  • activity against a greater proportion of the tumour cells will also be likely because of the “multi-targeted” nature of the RNA molecule of the invention.
  • targeting of several key pathways will “cover” more of the patient population. Hence, improved clinical outcomes are likely with treatment with the RNA molecules exemplified or taught herein.
  • the targeting of multiple disease-related transcripts with a single multitargeting interfering RNA molecule of the invention preferably allows full use of available RISC as opposed to the administration of multiple siRNA molecules, which could, in some cases, saturate the available intracellular machinery.
  • Targeting multiple sites within the same RNA target sequence can also be accomplished with the compositions and methods provided herein.
  • Many human diseases, including cancer and viral infections are characterized by RNA targets exhibiting high mutation rates. This increases the likelihood of resistance to nucleic acid therapeutics arising in these diseases, due to mutation of the target RNA.
  • Targeting multiple sites within the target RNA decreases the likelihood of such resistance arising, since at least two simultaneous mutations would be required for resistance.
  • the multi-targeting approach of multitargeting interfering RNAs eg CODEMIRs or VIROMIRs
  • Targeting of multiple sites within the same transcript may also produce synergistic effects on the inhibition of viral growth.
  • employing a mechanism or mechanisms requiring only partial complementarity with the target RNA can have an advantage in decreasing the possibility of developing resistance through point mutation.
  • the desired targets for any disease entity may be identified based on an approach or a mixture of approaches including, but not limited to, validated drug targets from literature and proprietary target discovery processes.
  • the target genes are then prioritized based on evidence supporting a key role for their products in the disease process of interest.
  • specific attention may need to be paid to the accuracy and/or relevance of the sequence to the disease of interest.
  • specific attention may need to be paid to the accuracy and/or relevance of the sequence to the disease of interest.
  • selective targeting of a specific splice variant or isoform may be desired and thus in such embodiments, the target sequence used in multitargeting interfering RNA design is preferably restricted to that isoform or variant present only in diseased tissue.
  • sequences of the target RNA or RNAs are preferably downloaded from public or proprietary databases or generated from sequencing experiments.
  • the entire mRNA sequence for each of VEGF-A and ICAM-1 was used. These sequences were searched to find sequences that are present in the coding strand for one target and the complement of the coding strand for another target.
  • the sequence 5′-AGTGACTGTCAC-3′ (SEQ ID NO: 1) was identified both in the ICAM-1 coding sequence and in the complement of the VEGF-A coding sequence.
  • This sequence was used to design a CODEMIR active against multiple targets, using each strand of the CODEMIR to target at least one of the target RNAs.
  • the sequence identified above and its complement were used as a centrally-located part of a CODEMIR duplex. Each strand of this central duplex was extended in the 5′ direction to provide full complementarity to the corresponding target, whereas each strand was extended in the 3′ direction so as to be complementary to its opposing strand in the CODEMIR duplex strand.
  • CODEMIRs comprise a sequence that is the complement of the seed.
  • the complementary sequence in the CODEMIRs is GUGACAGUCACU. (SEQ ID NO: 2)
  • CODEMIRs-16 and -17 were tested for activity against both VEGF-A and ICAM-1 targets in RPE cells.
  • RPE cells in culture were used to screen the anti-angiogenic CODEMIRs designed, as described above.
  • the human cell line, ARPE-19 was used.
  • ARPE-19 cells were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum and 10 mM glutamine.
  • ARPE cells were seeded at 4 ⁇ 10 3 cells per well in a 96 well tissue culture plate.
  • FACS analysis ARPE-19 cells were seeded at 2.5 ⁇ 10 4 cells per well in a 24 well tissue culture plate.
  • VEGF-A was assayed in the supernatant using a commercially available ELISA assay (R&D Systems) according to the manufacturer's instructions.
  • Cell surface ICAM-1 was assayed either by immunostaining followed by fluorescence activated cell sorting (FACS), by in situ immunostaining of cell-surface ICAM-1 in 96 well plates using colorimetric detection, or alternatively by ELISA of cell lysates using a commercial sICAM ELISA kit (R&D systems).
  • CODEMIRs were active modulators of the multiple targets.
  • CODEMIR-16 was more active in modulating VEGF-A and CODEMIR-17 was more active against ICAM-1, apparently as a result of the design symmetry. This is likely due to altered strand-loading bias.
  • the loading bias can be adjusted, for example, by introducing wobble G:U basepairs into the extremities of the duplex, or by expanding the CODEMIR to a 22-base duplex with symmetrical extremities. Variations of each of these types were explored.
  • CODEMIR-26 is a 22-base duplex that has 4 identical binding nucleotide pairs at each of the two termini of the duplex. As shown in FIG. 1 , CODEMIR-26 exhibited greatly increased ICAM-1 targeting compared to that of CODEMIR-16. Thus, the adjustments to the sequence were able to correct the loading bias observed with CODEMIR-16.
  • CODEMIRs-27 and -28 were designed to test whether disrupting strong G:C pairs at an end of the duplex region would also successfully overcome the loading bias observed with CODEMIR16.
  • the substitution of a C with a U in the 3′terminal region of the guide strands targeting VEGF-A was successful in changing the bias (e.g. CODEMIR-27).
  • CODEMIR-28 had similar activity to CODEMIR-27 where changes were made at the other end of the CODEMIR.
  • both strand loading bias and target activity can be controlled by introducing mismatches to disrupt the end of the duplex that is inefficiently loaded and simultaneously increase hybridization to the target.
  • CODEMIR-36 a variant of CODEMIR-16, both strands were designed to be entirely complementary to the respective target sequences; the resulting incompletely complementary duplex features several mismatches at the 5′extremity of the ICAM-1 guide sequence.
  • Table 1-1 The results for CODEMIR-36 (see Table 1-1) are shown in FIG. 1 .
  • the multitargeting interfering RNA (CODEMIRs) herein disclosed would be expected to be effective in multiple angiogenic diseases of the eye. This is because secreted VEGF-A plays a major role in all of these diseases (Witmer et al (2003) Prog Retin Eye Res, 22, 1-29), although ICAM-1 overexpression may be an early initiating event, particularly for diabetic retinopathy and macular edema (Funatsu et al., (2005) Opthalmology, 112, 806-16.; Joussen et al. (2002) Am J Pathol, 160, 501-9; Lu et al. (1999) Invest Opthalmol V is Sci, 40, 1808-12.
  • CODEMIRs are able to suppress both VEGF-A and ICAM-1 production by human retinal epithelium cells (ARPE-19 cell line). These cells are a major contributor to the production of these proteins in these ocular angiogenic diseases (Matsuoka et al., (2004) Br J Opthalmol, 88, 809-15, Yeh et al. (2004), Invest Opthalmol V is Sci, 45, 2368-73). RPE cells are also the primary site of uptake of foreign nucleic acids in the eye and, for these two reasons, are the appropriate cell model for evaluation of anti-angiogenic CODEMIRs in opthalmology.
  • CODEMIRs may also be suitable for the treatment of complex metabolic diseases such as type 2 diabetes.
  • Two potential gene targets for the treatment of this disease are glucose-6-phosphatase and Inppl1. Full transcript sequences were examined.
  • Candidate CODEMIRs from the best contiguous region of identity are shown for each case in Table 2-1.
  • Some modification of the CODEMIRs can be performed to tune the hybridization of the CODEMIR duplex, thereby affecting the loading bias.
  • Introduction of mismatches is one way of achieving this (for example see: Ohnishi et al. (2005) Biochem Biophys Res Commun. 329:516-21) and these mismatches can be chosen also for their ability to increase binding of the 3′ region of the effector strands to their respective target transcripts ( FIG. 2B ). In this situation, the CODEMIR duplex is then no longer composed of two strands with complete complementarity, similarly to CODEMIR-36.
  • CODEMIRs multitargeting interfering RNA molecules
  • these complementary sequences are CUGGGCGAGGCAG (SEQ ID NO: 21) and GUGGAUGUGGAG. (SEQ ID NO: 22) TABLE 2-1 Target sequences aligned with CODEMIRs for targeting Gluc6p and Inppl1.
  • central duplex 2 Inppl1 targeting strand 5′ CACC CUCCACAUCCAC CCCAC 3′ (SEQ ID NO: 29) Gluc6p targeting strand 3′ GUGG GAGGUGUAGGUG GGGUG 5′ (SEQ ID NO: 30)
  • the invention can be used to target proteins of interest that are likely to be mutated in chronic forms of disease. Mutations may be particularly prevalent in cancer and viral disease in which drug-resistant forms often evolve.
  • VIROMIRs were designed to target multiple sites in the Human Immunodeficiency Virus (HIV). The requirement for simultaneous mutation at several sites, in order to overcome the effects of such a VIROMIR, is likely to provide a high genetic hurdle to the emergence of resistant viral clones or quasispecies.
  • the genome of the HXB2 strain of HIV I serotype B (GenBank Accession K03455) was used as the principal sequence of interest and was examined with bioinformatics methods detailed elsewhere in this application to find seeds occurring at more than one location. All HIV I clade B isolates in the LANL database as of 1 Aug. 2005 which contain full sequences for any of the GAG, ENV, POL, TAT, VIF, VPR, VPU and NEF genes were used in these analyses.
  • K03455r is a partial sequence of the complement of the reference strain genome.
  • an effective RNA therapeutic of the invention should provide broad coverage of the affected population and it is obviously desirable to target sequences that are highly represented in this patient population. Therefore, the seed presented above might not cover a sufficient proportion of the population. Nevertheless, due to its unique size it was considered further in the exemplification of the invention.
  • the pNL4.3 assay is widely used in the field of HIV research as a valuable, validated screen for drugs active in HIV and was used by us to test candidate VIROMIRs.
  • the pNL4.3 assay is widely used in the field of HIV research as a valuable, validated screen for drugs active in HIV and was used by us to test candidate VIROMIRs.
  • the sequences of the HIV component of the pNL4.3 plasmid and that of the reference HIV strain (K03455) used in the design of the VIROMIR. Therefore, comparison of the sequence of the reference strain and the sequence of the pNL4.3 plasmid was carried out to confirm that the above-mentioned VIROMIR was targeting a sequence also present in the testing system.
  • Other testing systems such as viral challenge assays, fusion reporters, viral pseudoparticles among others, each representing any multitude of therapeutically relevant or irrelevant sequences could equally be considered.
  • VIROMIR duplex targeting these two seed sites is: 5′ UGCTGGUUUUGCGAUUCUAAA 3′ (SEQ ID NO: 37) 3′ GAACGACCAAAACGCUAAGAU 5′ (SEQ ID NO: 38) Analyzing the ends of the duplex, it will be apparent to one skilled in the art that the two strands would be unlikely to load equally, given the greater G/C content at one end relative to the other, therefore it would likely benefit from further optimization as discussed elsewhere in this invention.
  • VIROMIRs targeting HIV are most likely to be therapeutically effective as cell-expressed short hairpin RNAs (shRNAs) rather than as synthetic RNA duplexes because of a need for continued therapeutic cover to prevent re-emergence from latent sites.
  • shRNAs short hairpin RNAs
  • VM011 The sequences for VM011 were used in the design of an shRNA. Contiguous DNA sequences corresponding to: BamHI restriction site, G initiator, VIROMIR passenger, Xho loop sequence (ACTCGAGA), VIROMIR guide strand, polIII terminator and HindIII restriction site were assembled and prepared as dsDNA. They were then cloned into a pSIL vector under the control of a H1 promoter.
  • the encoded RNA folds into a hairpin structure, which is modified by the cellular Drosha and Dicer proteins to generate active VIROMIR RNA duplex(es).
  • the skilled artisan will also recognize that a number of variations of the design of the shRNA construct could be considered. These include but are not limited to: length, sequence and orientation of the shRNA duplex components (guide strand, passenger strand, precursors), length and sequence of the loop, choice of promoter, initiator and terminator sequences as well as the cloning strategies used to assemble the final construct.
  • HEK-293 cells were seeded at density of 2 ⁇ 10 ⁇ 5 cells in 1 ml Optimem medium/well in a 12-well plate. Cells were transfected 24 hr later with 200 ⁇ L DNA: Lipofectamine mix (200 ng pNL4.3 plasmid, 67 ng VIROMIR pSIL construct in 100 ⁇ L complexed with 2.7 ⁇ L Lipofectamine 2000 in Optimem). After changing the medium 24 hours later, the production of p24 was assayed by collection of the supernatant after a further 24 hours of incubation.
  • VM011 did not have any appreciable activity in this assay (data not shown), perhaps reflecting the lack of equivalent loading, as predicted from the analysis of the ends of the duplex. Nevertheless, one skilled in the art will appreciate that other design strategies (eg. alternative extension of the strands from the seed and its complement, or variation of the shRNA construct as described above) could be considered for the development of an active VIROMIR of this design, which when combined with appropriate screens such as the one used above, could be used to identify useful therapeutics.
  • multitargeting interfering RNAs can be utilized to target both the genome of the infectious agent and one or more key host “drivers” of the disease.
  • TNF-alpha is considered a major disease-associated factor in Hepatitis C Virus infection and its sequelae. Investigation of the genome of HCV and the TNF-alpha mRNA was undertaken.
  • This seed was selected because it is present in the HCV genome with a conservation of 94% in 155 isolates of genotypes 1a and 1b. This seed is actually present in two sites in HCV. We then considered the nucleotides in the 3′ direction from this seed to establish which site should be primarily considered in the design of the duplex.
  • the extended sequences for the sites (+6 bases to the 3′ end) were as follows: ACTCCCCTGTGAGGA (site #1) (SEQ ID NO: 42) ACTCCCCTGACGCCG (site #2) (SEQ ID NO: 43)
  • the seed is in the 5′NTR of HCV and 3′UTR of TNFalpha. Shown below is the location of the seed in the HCV sequence and in the antiparallel sequence for TNFalpha: (SEQ ID NO: 44) 5′ TGATGGGGGCGACACTCCACCATGAATC ACTCCCCTG TGAGGAAC TACTGTCTTCACGCAGAAAGC 3′ HCV (SEQ ID NO: 45) 3′ ACTGAATAGTAGGGCGATTACAGACACA ACTCCCCTG GGGAGCAG AGGCTCAGCAATGAGTGACAG 5′ TNFar
  • the required extension for the duplex of the required length is, for example, 5 bases in the 3′ direction of the target and 5 bases in the 5′ direction as the seed is usually in the middle of the double stranded duplex (excluding the overhangs).
  • the resulting two strands will have an equivalent portion of complete complementarity with their respective targets when the process outlined below is followed. This should ensure that binding of the resulting two strands should be comparable.
  • the extension by 5 on each side would create a duplex of 20 whereas extension of 4 plus 5 or 5 plus 4 would yield a duplex of 19 nucleotides.
  • Other permutations are equally permissible depending on the lengths of the seed and the desired duplex.
  • a means of generating one of the strands of the duplex is as follows:
  • the opposite strand is then the complement of the first guide strand: 5′-ACACAACUCCCCUGUGAGG-3′ (SEQ ID NO: 49) such that the duplex is: 5′-CCUCACAGGGGAGUUGUGU-3′ (SEQ ID NO: 48) 3′-GGAGUGUCCCCUCAACACA-5′ (SEQ ID NO: 49)
  • the two guide strands have predicted binding to the two targets of: HCV 5′ GACACUCCACCAUGAAUCACUCCCCUGUGAGGA 3′ (SEQ ID NO: 50) Guide#1 3′ UGUGUUGAGGGGACACUCC 5′ (SEQ ID NO: 48) mfe: ⁇ 35.0 kcal/mol TNFa 5′ GCCUCUGCUCCCCAGGGGAGUUGUGUC 3′ (SEQ ID NO: 51) Guide#2 3′ GGGAGUGUCCCCUCAACACA 5′ (SEQ ID NO: 49) mfe: ⁇ 35.0 kcal/mol
  • the duplex could be extended with further complementarity to the HCV sequence, possibly: 5′-UCCUCACAGGGGAGUUGUGU-3′ (SEQ ID NO: 52) 3′-AGGAGUGUCCCCUCAACACA-5′ (SEQ ID NO: 53)
  • a duplex for which the TNFa-targeting strand is mutated but still capable of binding to the target and the corresponding strand is changed to match could be: 5′-CCUCACAGGGGAGUUGUGC-3′ (SEQ ID NO: 54) 3′-GGAGUGUCCCCUCAACACG-5′ (SEQ ID NO: 55)
  • overhangs can be added. It may be beneficial to make those complementary to the intended target so as to enhanced improved binding of the tail region.
  • the added bases may be selected so as to provide predicted binding to a specified further region in the target RNA. For example, in the above in silico binding result a large bulge is predicted to be formed from the binding of the first guide strand to the HCV target RNA. The choice of overhangs could be guided by the desire to reduce the length of that bulge. Other alternatives are to add bases complementary to the target to provide an extension of the binding indicated in silico. So, as an example, the duplex generated above could be further extended using the information from the in silico hybridization to further define the bases required. 5′-CCUCACAGGGGAGUUGUGCCC-3′ (SEQ ID NO: 57) 3′-UCGGAGUGUCCCCUCAACACG-5′ (SEQ ID NO: 58)
  • sequence could be empirically extended by adding UU: 5′-CCUCACAGGGGAGUUGUGCUU-3′ (SEQ ID NO: 59) 3′-UUGGAGUGUCCCCUCAACACG-5′ (SEQ ID NO: 60)
  • synthetic multitargeting interfering RNA duplexes will comprise the seed and its corresponding complement (5′ CAGGGGAGU 3′). (SEQ ID NO: 46)
  • synthetic multitargeting interfering RNA duplexes will comprise the seed and its corresponding complement (5′ AGGGCUCCAGGCG 3′ (SEQ ID NO: 63) or 5′ GCUGGCCGAGGAG 3′). (SEQ ID NO: 64)
  • ARPE-19 cells were transfected with 40 nM duplex RNA and VEGF (ELISA) or ICAM (FACS) expression was assayed 48 hours post-transfection.
  • VEGF VEGF
  • ICAM ICAM
  • CODEMIRs and other multitargeting interfering RNA of the invention could be tested in various preclinical models known to those skilled in the art.
  • CODEMIRs-26-28 could be tested in a retinopathy of prematurity model.
  • This model is well known to those working in the field of ocular angiogenesis and is used extensively as one of several models for the development of drugs active against the diseases of interest (AMD, diabetic retinopathy etc).
  • the study could comprise of a suitable number of mouse or rat neonate pups equally divided into treatment groups.
  • the treatment groups could include negative controls such as vehicle, irrelevant or scrambled sequence controls plus a number of multitargeting interfering RNA.
  • siRNA to VEGF as known comparators.
  • CODEMIRs could alternatively be evaluated in vivo for inhibition of disease-related angiogenesis using the laser-induced Choroidal Neovascularization (CNV) model in rats or primates.
  • CNV Choroidal Neovascularization
  • animals under general anaesthesia have their pupils dilated and retina photographed.
  • Choroidal neovascularisation is induced by krypton laser photocoagulation. This is performed using laser irradiation to either the left or alternatively, the right eye of each animal from all treatment groups through a slit lamp. A total of 6-11 laser burns are generally applied to each eye surrounding the optic nerve at the posterior pole.
  • the multitargeting interfering RNA are injected into the affected eyes.
  • the suitable time can be the day following laser induction, or for an assessment against established CNV, the injections can be performed several days or weeks following injury.
  • Intravitreal injections of the oligonucleotides are performed by inserting a 30- or 32-gauge needle into the vitreous. Insertion and infusion can be performed and directly viewed through an operating microscope. Care is taken not to injure the lens or the retina.
  • the test compounds are placed in the superior and peripheral vitreous cavity.
  • the neoangiogenesis is evaluated by either imaging and/or direct sampling (eg histology, immunohistochemistry). In all cases, the assessment of CNV is best performed by a skilled operator blinded to the actual treatment to ensure a lack of bias in the recording of the information.
  • fluorescein angiography is used to image the vessels and areas of vascular leakage in the retina. This is performed on all of the animals following the intraperitoneal or intravenous injection of sodium fluorescein. The retinal vasculature is then photographed using the same camera as used for CFP but with a barrier filter for fluorescein angiography added. Single photographs can be taken at 0.5-1 minute intervals immediately after the administration of sodium fluorescein. The extent of fluorescein leakage is scored by a trained operator. The mean severity scores from each of the time points are compared by a suitable statistical analysis and differences considered significant at p ⁇ 0.05. In addition, the frequency of each lesion score is counted, tabulated and represented graphically.
  • rats can be euthanased at selected time points following treatment (for example 7, 14 and 28 days post injection) and eyes examined by conventional histopathology. A reduction in the number and severity of lesions is expected to be seen with samples treated by active oligonucleotides of the invention.
  • non-limiting examples including testing the multitargeting interfering RNA of the invention in other preclinical models such as those that are well known to those skilled in the art.
  • a non-exhaustive list includes pulmonary fibrosis (bleomycin induced), paw inflammation (carrageen), joint arthritis, diabetes, viral infection, tumour xenografts etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US11/602,804 2005-11-21 2006-11-21 Multitargeting interfering RNAs having two active strands and methods for their design and use Abandoned US20070269815A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/602,804 US20070269815A1 (en) 2005-11-21 2006-11-21 Multitargeting interfering RNAs having two active strands and methods for their design and use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73864005P 2005-11-21 2005-11-21
US73844105P 2005-11-21 2005-11-21
US11/602,804 US20070269815A1 (en) 2005-11-21 2006-11-21 Multitargeting interfering RNAs having two active strands and methods for their design and use

Publications (1)

Publication Number Publication Date
US20070269815A1 true US20070269815A1 (en) 2007-11-22

Family

ID=38048226

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/602,804 Abandoned US20070269815A1 (en) 2005-11-21 2006-11-21 Multitargeting interfering RNAs having two active strands and methods for their design and use
US12/124,629 Expired - Fee Related US8097715B2 (en) 2005-11-21 2008-05-21 Multitargeting interfering RNAs having two active strands and methods for their design and use
US12/124,590 Abandoned US20090239816A1 (en) 2005-11-21 2008-05-21 Multitargeting Interfering RNAs And Methods Of Their Use And Design

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/124,629 Expired - Fee Related US8097715B2 (en) 2005-11-21 2008-05-21 Multitargeting interfering RNAs having two active strands and methods for their design and use
US12/124,590 Abandoned US20090239816A1 (en) 2005-11-21 2008-05-21 Multitargeting Interfering RNAs And Methods Of Their Use And Design

Country Status (6)

Country Link
US (3) US20070269815A1 (enExample)
EP (2) EP1951736A4 (enExample)
JP (2) JP2009516518A (enExample)
AU (2) AU2006315102A1 (enExample)
CA (2) CA2630952A1 (enExample)
WO (2) WO2007056826A1 (enExample)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047909A1 (en) * 2007-03-02 2010-02-25 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
US20100112687A1 (en) * 2007-03-02 2010-05-06 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
WO2010144058A1 (en) 2009-06-10 2010-12-16 Temasek Life Sciences Laboratory Limited Virus induced gene silencing (vigs) for functional analysis of genes in cotton.
US20120071539A1 (en) * 2006-12-12 2012-03-22 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
US8772262B2 (en) 2010-10-14 2014-07-08 Mie University Preventive or therapeutic agent for fibrosis
US20160160212A1 (en) * 2014-06-23 2016-06-09 Monsanto Technology Llc Compositions and Methods for Regulating Gene Expression via RNA Interference
US9580708B2 (en) 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
US9790494B2 (en) 2012-09-14 2017-10-17 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers
US9988634B2 (en) 2010-03-08 2018-06-05 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
US10059941B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10058623B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating UTRN expression
US10100306B2 (en) 2013-11-04 2018-10-16 Monsanto Technology Llc Compositions and methods for controlling arthropod parasite and pest infestations
WO2018204398A1 (en) * 2017-05-01 2018-11-08 Donald Danforth Plant Science Center Rnai approach for crop pest protection
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
US10174328B2 (en) 2013-10-04 2019-01-08 Translate Bio Ma, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
US10174323B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating ATP2A2 expression
US10240161B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
US10334848B2 (en) 2014-01-15 2019-07-02 Monsanto Technology Llc Methods and compositions for weed control using EPSPS polynucleotides
US10378012B2 (en) 2014-07-29 2019-08-13 Monsanto Technology Llc Compositions and methods for controlling insect pests
US10557138B2 (en) 2013-12-10 2020-02-11 Beeologics, Inc. Compositions and methods for virus control in Varroa mite and bees
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US10597676B2 (en) 2013-07-19 2020-03-24 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US10609930B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
US10612019B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
US10655128B2 (en) 2012-05-16 2020-05-19 Translate Bio Ma, Inc. Compositions and methods for modulating MECP2 expression
US10655136B2 (en) 2015-06-03 2020-05-19 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10801028B2 (en) 2009-10-14 2020-10-13 Beeologics Inc. Compositions for controlling Varroa mites in bees
US10808249B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10883103B2 (en) 2015-06-02 2021-01-05 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
US10888579B2 (en) 2007-11-07 2021-01-12 Beeologics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US10968449B2 (en) 2015-01-22 2021-04-06 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US11091770B2 (en) 2014-04-01 2021-08-17 Monsanto Technology Llc Compositions and methods for controlling insect pests
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053019A2 (en) * 2006-11-02 2008-05-08 Dsm Ip Assets B.V. Method for reducing the expression of a gene in a filamentous fungal cell
WO2008094516A2 (en) 2007-01-29 2008-08-07 City Of Hope Multi-targeting short interfering rnas
US20080311040A1 (en) * 2007-03-06 2008-12-18 Flagship Ventures METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
US8399248B2 (en) 2007-05-03 2013-03-19 Merck Sharp & Dohme Corp. Methods of using MIR34 as a biomarker for TP53 functional status
AU2008251037A1 (en) * 2007-05-15 2008-11-20 Johnson & Johnson Research Pty Limited Suppression of viruses involved in respiratory infection or disease
WO2009035539A2 (en) * 2007-09-05 2009-03-19 Nt Omics Inc. Long interfering nucleic acid duplexes targeting multiple rna targets
CA2705325C (en) 2007-11-09 2016-11-01 The Board Of Regents Of The University Of Texas System Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
GB2468477A (en) * 2009-03-02 2010-09-15 Mina Therapeutics Ltd Double stranded RNA molecule comprising siRNA and miRNA precursors
US20130023578A1 (en) * 2009-12-31 2013-01-24 Samyang Biopharmaceuticals Corporation siRNA for inhibition of c-Met expression and anticancer composition containing the same
ES2673960T3 (es) * 2011-12-22 2018-06-26 Ionis Pharmaceuticals, Inc. Métodos para modular la expresión de un transcrito-1 de adenocarcinoma en pulmón asociado a metástasis (MALAT-1)
US9212363B2 (en) * 2012-05-11 2015-12-15 City Of Hope RNAI molecules with non-watson crick pairing based on artificial mutation consensus sequences to counter escape mutations
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
KR20150103280A (ko) * 2013-01-08 2015-09-09 베니텍 바이오파마 리미티드 연령-관련 황반 변성 치료
EP3122365B1 (en) 2014-03-25 2023-05-03 Arcturus Therapeutics, Inc. Transthyretin allele selective una oligomers for gene silencing
CA2946719C (en) * 2014-03-25 2023-09-26 Arcturus Therapeutics, Inc. Una oligomers having reduced off-target effects in gene silencing
US9856475B2 (en) 2014-03-25 2018-01-02 Arcturus Therapeutics, Inc. Formulations for treating amyloidosis
HK1244035A1 (en) 2014-12-15 2018-07-27 Bonac Corporation Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression
WO2016161299A1 (en) 2015-04-01 2016-10-06 Arcturus Therapeutics, Inc. Therapeutic una oligomers and uses thereof
WO2017015671A1 (en) 2015-07-23 2017-01-26 Arcturus Therapeutics, Inc. Compositions for treating amyloidosis
US10556019B2 (en) * 2015-08-21 2020-02-11 Universitätsklinikum Jena Human microRNAs for treatment of malignant tumours
US11279932B2 (en) 2019-02-27 2022-03-22 Ionis Pharmaceuticals, Inc. Modulators of MALAT1 expression
JP2024522850A (ja) * 2021-06-23 2024-06-21 ヴェルサメブ アーゲー 遺伝子の発現をモジュレートするための組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019453A2 (en) * 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003070912A2 (en) * 2001-06-06 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050187174A1 (en) * 2001-05-18 2005-08-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050048529A1 (en) * 2002-02-20 2005-03-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
CA2513679A1 (en) * 2003-01-17 2004-08-05 University Of Florida Small interference rna gene therapy
EP1797183B1 (en) * 2004-09-02 2012-08-01 Yale University Regulation of oncogenes by micrornas

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071539A1 (en) * 2006-12-12 2012-03-22 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
US20100047909A1 (en) * 2007-03-02 2010-02-25 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
US20100112687A1 (en) * 2007-03-02 2010-05-06 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
US10888579B2 (en) 2007-11-07 2021-01-12 Beeologics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2010144058A1 (en) 2009-06-10 2010-12-16 Temasek Life Sciences Laboratory Limited Virus induced gene silencing (vigs) for functional analysis of genes in cotton.
US10801028B2 (en) 2009-10-14 2020-10-13 Beeologics Inc. Compositions for controlling Varroa mites in bees
US11812738B2 (en) 2010-03-08 2023-11-14 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
US9988634B2 (en) 2010-03-08 2018-06-05 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
US8772262B2 (en) 2010-10-14 2014-07-08 Mie University Preventive or therapeutic agent for fibrosis
US9273314B2 (en) 2010-10-14 2016-03-01 Mie University Preventive or therapeutic agent for fibrosis
US10125366B2 (en) 2010-10-14 2018-11-13 Mie University Preventive or therapeutic agent for fibrosis
US9637743B2 (en) 2010-10-14 2017-05-02 Mie University Preventive or therapeutic agent for fibrosis
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
US10808249B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US9732340B2 (en) 2011-09-14 2017-08-15 Translate Bio Ma, Inc. Multimeric oligonucleotides compounds having cleavable linkers
US10704046B2 (en) 2011-09-14 2020-07-07 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
US10093924B2 (en) 2011-09-14 2018-10-09 Translate Bio Ma, Inc. Multimetric oligonucleotide compounds
US9732341B2 (en) 2011-09-14 2017-08-15 Translate Bio Ma, Inc. Methods of delivering multiple targeting oligonucleotides to a cell using cleavable linkers
US9580708B2 (en) 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
US11788089B2 (en) 2012-05-16 2023-10-17 The General Hospital Corporation Compositions and methods for modulating MECP2 expression
US10059941B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10058623B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating UTRN expression
US10655128B2 (en) 2012-05-16 2020-05-19 Translate Bio Ma, Inc. Compositions and methods for modulating MECP2 expression
US10174323B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating ATP2A2 expression
US10240161B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
US10240162B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
US10934555B2 (en) 2012-05-24 2021-03-02 Monsanto Technology Llc Compositions and methods for silencing gene expression
US10844375B2 (en) 2012-09-14 2020-11-24 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers
US9790494B2 (en) 2012-09-14 2017-10-17 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
US10612019B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
US10609930B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US10597676B2 (en) 2013-07-19 2020-03-24 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US11377667B2 (en) 2013-07-19 2022-07-05 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US10174328B2 (en) 2013-10-04 2019-01-08 Translate Bio Ma, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
US10927374B2 (en) 2013-11-04 2021-02-23 Monsanto Technology Llc Compositions and methods for controlling arthropod parasite and pest infestations
US10100306B2 (en) 2013-11-04 2018-10-16 Monsanto Technology Llc Compositions and methods for controlling arthropod parasite and pest infestations
US10557138B2 (en) 2013-12-10 2020-02-11 Beeologics, Inc. Compositions and methods for virus control in Varroa mite and bees
US10334848B2 (en) 2014-01-15 2019-07-02 Monsanto Technology Llc Methods and compositions for weed control using EPSPS polynucleotides
US11091770B2 (en) 2014-04-01 2021-08-17 Monsanto Technology Llc Compositions and methods for controlling insect pests
CN106795515B (zh) * 2014-06-23 2021-06-08 孟山都技术公司 用于经由rna干扰调控基因表达的组合物和方法
CN106795515A (zh) * 2014-06-23 2017-05-31 孟山都技术公司 用于经由rna干扰调控基因表达的组合物和方法
US10988764B2 (en) * 2014-06-23 2021-04-27 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
US20160160212A1 (en) * 2014-06-23 2016-06-09 Monsanto Technology Llc Compositions and Methods for Regulating Gene Expression via RNA Interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US11124792B2 (en) 2014-07-29 2021-09-21 Monsanto Technology Llc Compositions and methods for controlling insect pests
US10378012B2 (en) 2014-07-29 2019-08-13 Monsanto Technology Llc Compositions and methods for controlling insect pests
US10968449B2 (en) 2015-01-22 2021-04-06 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US10883103B2 (en) 2015-06-02 2021-01-05 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
US10655136B2 (en) 2015-06-03 2020-05-19 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
CN110914429A (zh) * 2017-05-01 2020-03-24 唐纳德丹佛斯植物科学中心 用于作物害虫防护的RNAi方法
WO2018204398A1 (en) * 2017-05-01 2018-11-08 Donald Danforth Plant Science Center Rnai approach for crop pest protection

Also Published As

Publication number Publication date
US20090192103A1 (en) 2009-07-30
CA2630952A1 (en) 2007-05-24
EP1951263A1 (en) 2008-08-06
AU2006315102A1 (en) 2007-05-24
EP1951736A1 (en) 2008-08-06
AU2006315099C1 (en) 2013-01-10
EP1951736A4 (en) 2009-12-16
JP5078904B2 (ja) 2012-11-21
US20090239816A1 (en) 2009-09-24
JP2009516518A (ja) 2009-04-23
EP1951263A4 (en) 2009-11-18
WO2007056829A1 (en) 2007-05-24
WO2007056826A1 (en) 2007-05-24
AU2006315099A1 (en) 2007-05-24
CA2630932A1 (en) 2007-05-24
AU2006315099B2 (en) 2012-07-05
JP2009516517A (ja) 2009-04-23
US8097715B2 (en) 2012-01-17

Similar Documents

Publication Publication Date Title
US8097715B2 (en) Multitargeting interfering RNAs having two active strands and methods for their design and use
JP6236498B2 (ja) 非対称性干渉ｒｎａの組成物およびその使用
KR101012595B1 (ko) 작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물
US7687475B2 (en) RNA interference in respiratory epithelial cells
US20120252880A1 (en) Oligonucleotide Complex Compositions And Methods Of Use As Gene Alteration Tools
JPWO2008139938A1 (ja) ヒトパピローマウイルス１６型遺伝子を標的とする二本鎖核酸分子及びそれを含む医薬
US9222090B2 (en) RNA interference target for treating AIDS
US20060293267A1 (en) Dual functional oligonucleotides for use as anti-viral agents
KR20250155023A (ko) Sod1을 표적으로 하는 올리고뉴클레오타이드
KR20170058979A (ko) 헌팅턴병 일배체형에 대한 대립 유전자-특이적 치료
RU2385939C1 (ru) Генетические конструкции, атакующие шесть новых мишеней рнк-интерференции в транскриптах вируса иммунодефицита человека 1 типа и подавляющие репродукцию вируса в клетках человека
CN109266684B (zh) 一种构建病原感染敏感性动物模型的方法
US20100286238A1 (en) Suppression of viruses involved in respiratory infection or disease
US20250144241A1 (en) Methods of targeting repetitive rna in huntington's disease

Legal Events

Date Code Title Description
AS Assignment

Owner name: JOHNSON & JOHNSON RESEARCH PTY LIMITED, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIVORY, LAURENT;POIDINGER, MICHAEL;BIRKETT, DONALD;AND OTHERS;REEL/FRAME:018751/0309

Effective date: 20070109

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION